

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Non-infectious chemotherapy-associated acute... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-444/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-444" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy" />
    
            <meta name="og:title" content="F1000Research Article: Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.">
            <meta name="og:description" content="Read the latest article version by Kjeld Schmiegelow, Klaus M&uuml;ller, Signe Sloth Mogensen, Pernille Rudebeck Mogensen, Benjamin Ole Wolthers, Ulrik Kristoffer Stoltze, Ruta Tuckuviene, Thomas Frandsen, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11611">
            <meta name="article-id" content="10768">
            <meta name="dc.title" content="Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy">
            <meta name="dc.description" content="During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.">
            <meta name="dc.subject" content="acute lymphoblastic leukaemia, ALL, chemotherapy, side effects, toxicities">
            <meta name="dc.creator" content="Schmiegelow, Kjeld">
            <meta name="dc.creator" content="M&uuml;ller, Klaus">
            <meta name="dc.creator" content="Mogensen, Signe Sloth">
            <meta name="dc.creator" content="Mogensen, Pernille Rudebeck">
            <meta name="dc.creator" content="Wolthers, Benjamin Ole">
            <meta name="dc.creator" content="Stoltze, Ulrik Kristoffer">
            <meta name="dc.creator" content="Tuckuviene, Ruta">
            <meta name="dc.creator" content="Frandsen, Thomas">
            <meta name="dc.date" content="2017/04/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10768.1">
            <meta name="dc.source" content="F1000Research 2017 6:444">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="acute lymphoblastic leukaemia">
            <meta name="prism.keyword" content="ALL">
            <meta name="prism.keyword" content="chemotherapy">
            <meta name="prism.keyword" content="side effects">
            <meta name="prism.keyword" content="toxicities">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/04/07">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="444">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10768.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-444">
            <meta name="citation_title" content="Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy">
            <meta name="citation_abstract" content="During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.">
            <meta name="citation_description" content="During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.">
            <meta name="citation_keywords" content="acute lymphoblastic leukaemia, ALL, chemotherapy, side effects, toxicities">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kjeld Schmiegelow">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author_institution" content="Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark">
            <meta name="citation_author" content="Klaus M&uuml;ller">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author_institution" content="Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark">
            <meta name="citation_author" content="Signe Sloth Mogensen">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author" content="Pernille Rudebeck Mogensen">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author_institution" content="Department of Diabetes and Metabolism, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author" content="Benjamin Ole Wolthers">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author" content="Ulrik Kristoffer Stoltze">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_author" content="Ruta Tuckuviene">
            <meta name="citation_author_institution" content="Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark">
            <meta name="citation_author" content="Thomas Frandsen">
            <meta name="citation_author_institution" content="Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark">
            <meta name="citation_publication_date" content="2017/04/07">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="444">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10768.1">
            <meta name="citation_firstpage" content="444">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-444/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-444.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11611 /> <input type=hidden id=articleId name=articleId value=10768 /> <input type=hidden id=xmlUrl value="/articles/6-444/v1/xml"/> <input type=hidden id=xmlFileName value="-6-444-v1.xml"> <input type=hidden id=article_uuid value=10a9715d-bc39-4a87-8c5c-181ab38a22c9 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10768.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10768.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-444"
  },
  "headline": "Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy",
  "datePublished": "2017-04-07T09:21:48",
  "dateModified": "2017-04-07T09:21:48",
  "author": [
    {
      "@type": "Person",
      "name": "Kjeld Schmiegelow"
    },    {
      "@type": "Person",
      "name": "Klaus M&uuml;ller"
    },    {
      "@type": "Person",
      "name": "Signe Sloth Mogensen"
    },    {
      "@type": "Person",
      "name": "Pernille Rudebeck Mogensen"
    },    {
      "@type": "Person",
      "name": "Benjamin Ole Wolthers"
    },    {
      "@type": "Person",
      "name": "Ulrik Kristoffer Stoltze"
    },    {
      "@type": "Person",
      "name": "Ruta Tuckuviene"
    },    {
      "@type": "Person",
      "name": "Thomas Frandsen"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-444",
            "name": "Non-infectious chemotherapy-associated acute toxicities during childhood..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Non-infectious chemotherapy-associated acute toxicities during childhood... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11611 data-id=10768 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10768.1" data-recommended="" data-doi="10.12688/f1000research.10768.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-444/v1/pdf?article_uuid=10a9715d-bc39-4a87-8c5c-181ab38a22c9" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10768-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10768-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10768-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Schmiegelow K, Müller K, Mogensen SS <em>et al.</em> Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):444 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10768.1" target=_blank>https://doi.org/10.12688/f1000research.10768.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10768-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10768 id=track-article-signin-10768 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10768?target=/articles/6-444">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11611 /> <input name=articleId type=hidden value=10768 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:Kjeld.Schmiegelow@regionh.dk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kjeld Schmiegelow</span></a><a href="https://orcid.org/0000-0002-0829-4993" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0829-4993</div><sup>1,2</sup>,&nbsp;</span><span class="">Klaus M&uuml;ller<sup>1,2</sup>,&nbsp;</span><span class="">Signe Sloth Mogensen<sup>1</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Pernille Rudebeck Mogensen<sup>1,3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Benjamin Ole Wolthers<sup>1</sup>,&nbsp;</span><span class="">Ulrik Kristoffer Stoltze<sup>1</sup>,&nbsp;</span><span class="">Ruta Tuckuviene<sup>4</sup>,&nbsp;</span><span class="">Thomas Frandsen<a href="https://orcid.org/0000-0001-8495-5274" target=_blank id=author-orcid-7><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-7><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8495-5274</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:Kjeld.Schmiegelow@regionh.dk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kjeld Schmiegelow</span></a><a href="http://orcid.org/0000-0002-0829-4993" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0829-4993</div><sup>1,2</sup>,&nbsp;</span><span class="">Klaus M&uuml;ller<sup>1,2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Signe Sloth Mogensen<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Pernille Rudebeck Mogensen<sup>1,3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Benjamin Ole Wolthers<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Ulrik Kristoffer Stoltze<sup>1</sup>,&nbsp;</span><span class="">Ruta Tuckuviene<sup>4</sup>,&nbsp;</span><span class="">Thomas Frandsen<a href="http://orcid.org/0000-0001-8495-5274" target=_blank id=mauthor-orcid-7><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-7><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8495-5274</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Apr 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10768.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark<br/> <sup>2</sup> Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark<br/> <sup>3</sup> Department of Diabetes and Metabolism, University Hospital Rigshospitalet, Copenhagen, Denmark<br/> <sup>4</sup> Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21725-21478></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=21724-21479></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=3116-21477></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> acute lymphoblastic leukaemia, ALL, chemotherapy, side effects, toxicities </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Kjeld Schmiegelow (<a href="mailto:Kjeld.Schmiegelow@regionh.dk">Kjeld.Schmiegelow@regionh.dk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Kjeld Schmiegelow </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by the Danish Cancer Society and the Danish Childhood Cancer Foundation. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Schmiegelow K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Schmiegelow K, Müller K, Mogensen SS <em>et al.</em> Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):444 (<a href="https://doi.org/10.12688/f1000research.10768.1" target=_blank>https://doi.org/10.12688/f1000research.10768.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Apr 2017, <b>6</b>(F1000 Faculty Rev):444 (<a href="https://doi.org/10.12688/f1000research.10768.1" target=_blank>https://doi.org/10.12688/f1000research.10768.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Apr 2017, <b>6</b>(F1000 Faculty Rev):444 (<a href="https://doi.org/10.12688/f1000research.10768.1" target=_blank>https://doi.org/10.12688/f1000research.10768.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d252e289>Introduction</h2><p class="" id=d252e292>The best contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) now yields 5-year overall survival (OS) rates above 90%, which reflects intensified chemotherapy with treatment stratification directed by the somatic mutations and early response to chemotherapy, better use of conventional anti-leukemic agents, and improved supportive care, including broad-spectrum antibiotics to combat opportunistic infections<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. However, a significant proportion of leukemic deaths, not least for lower-risk patients, are caused by therapy rather than by the leukemia itself, and this is just the tip of the toxicity iceberg<sup><a href="#ref-3">3</a></sup>. Nearly all patients encounter mucositis and serious, though manageable, infections, and although various other severe, acute toxicities individually have relatively low incidences, almost 50% of all patients will be affected by at least one of these<sup><a href="#ref-4">4</a></sup>. Whereas recent high-throughput, cost-effective technologies have revolutionized our insight into the somatic mutational landscape of ALL, disease pathogenesis, and drug resistance mechanisms<sup><a href="#ref-5">5</a></sup>, our understanding of non-infectious chemotherapy-associated acute toxicities remains limited, including how to prevent and treat them. This reflects their rarity (calling for international collaboration), diverse definitions and capture strategies across study groups, lack of tissue specimens to map pathogenesis, and uncertain associations with common germline DNA variants<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. This review summarizes recent advancements in the exploration of non-infectious, chemotherapy-associated acute toxicities and outlines strategies for future research.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e324>The toxicity scenario</h2><p class="" id=d252e327>Every organ can be affected by acute side effects of anti-leukemic chemotherapy, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis, ON), thromboembolism (TE), sinusoidal obstruction syndrome (SOS), endocrinopathies (especially corticosteroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate (HD-MTX)-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Other toxicities, including myopathy and some rare inflammatory toxicities (for example, epidermolysis), will not be addressed in this review.</p><p class="" id=d252e330>Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and comparison of their frequency across various anti-leukemic treatment programs has been hampered by wide diversities in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences. The toxicities have traditionally been defined and graded according to the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)<sup><a href="#ref-8">8</a></sup>. However, these are generic in their grading and frequently inappropriate for children<sup><a href="#ref-9">9</a></sup> and for the acute toxicities seen during childhood ALL therapy. Accordingly, 15 international childhood ALL study groups (Ponte di Legno Toxicity Working Group, or PTWG) have developed consensus definitions for 14 acute toxicities<sup><a href="#ref-7">7</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e348>Mucositis</h2><p class="" id=d252e351>Mucositis is a debilitating adverse effect that is reported to occur in at least 40% of patients after high-dose anti-metabolites or DNA-damaging drugs, including high-dose alkylating agents given as part of conditioning therapy prior to hematopoietic stem cell transplantation (hSCT)<sup><a href="#ref-10">10</a>–<a href="#ref-13">13</a></sup>.</p><p class="" id=d252e361>Risk factors for mucositis include low body weight, reduced renal function, low neutrophil counts, and elevated pre-therapeutic levels of inflammatory mediators<sup><a href="#ref-10">10</a>,<a href="#ref-12">12</a>,<a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. In addition, the risk of severe mucositis has, albeit with conflicting results, been associated with common DNA polymorphisms, including the folate pathway methylenetetrahydrofolate reductase (<i>MTHFR</i>, particularly C677T)<sup><a href="#ref-16">16</a></sup> and DNA repair<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d252e388>Oral mucositis ranges from soreness with erythema and edema to painful, ulcerative mucositis requiring narcotic analgesics, which may lead to poor nutritional status<sup><a href="#ref-18">18</a></sup>. Intestinal mucositis typically develops in parallel with abdominal pain, diarrhea or constipation, nausea, and vomiting, but oral and intestinal mucositis may not coincide<sup><a href="#ref-18">18</a></sup>. They both tend to peak at the time of neutrophil nadir 10 to 14 days after chemotherapy and typically resolve during the subsequent 5 to 10 days.</p><p class="" id=d252e399>Gastrointestinal mucositis reflects release of damage-associated molecular patterns that are sensed by pattern recognition receptors such as Toll like-receptors, causing release of inflammatory cytokines propagating an inflammatory response<sup><a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup>. This is followed by an ulceration phase and finally resolution<sup><a href="#ref-19">19</a></sup>. The normal intestinal microbiome may play a protective role by stimulating endothelial cell proliferation and mucous production, and intestinal dysbiosis due to chemotherapy and antibiotics could aggravate mucositis, but this awaits clinical validation<sup><a href="#ref-21">21</a>–<a href="#ref-23">23</a></sup>. Severe mucositis disrupts the intestinal immunological barrier and is a risk factor for systemic infections, although it has been most intensively studied in the hSCT setting<sup><a href="#ref-22">22</a>,<a href="#ref-24">24</a></sup>. Accordingly, intestinal mucositis defined by hypocitrullinemia<i></i> reflecting a reduced population of functional enterocytes may be better than neutropenia at defining the risk period for bacteremia<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d252e435>Although several studies have demonstrated temporal associations between gastrointestinal toxicity, systemic inflammation, and fever, infections can be proven in only less than 50% of febrile neutropenic episodes<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>, and the cause in microbiologically negative cases is more likely systemic inflammation—for example, C-reactive protein, interleukin-6, and <i>in vitro</i> cytokine production—than opportunistic microorganisms<sup><a href="#ref-13">13</a>,<a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup>. This has led to the introduction of febrile mucositis as a complementary term to the ubiquitous febrile neutropenia<sup><a href="#ref-28">28</a></sup>. hSCT studies have linked systemic inflammation to adverse outcome and increased treatment-related mortality<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. It is conceivable, but not yet shown, that this also holds true for ALL.</p><p class="" id=d252e469>Numerous interventions have been tested for the prevention or amelioration of mucositis as reviewed and regularly updated by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology<sup><a href="#ref-32">32</a></sup>. Parenteral non-steroid anti-inflammatory drugs, anti-epileptics, neuroleptics, and opioids are still the mainstay of pain control, despite often being insufficiently effective<sup><a href="#ref-33">33</a></sup>. Probiotics containing lactobacillus species seem to reduce chemotherapy-induced diarrhea and mucositis but have been tested only in highly specific treatment settings and await formal testing in patients with chemotherapy-induced neutropenia and mucosa barrier dysfuntion<sup><a href="#ref-34">34</a>–<a href="#ref-37">37</a></sup> (NCT02544685). Other less established interventions of some efficacy include intravenous glutamine, cryotherapy, recombinant keratinocyte growth factor-1, and low-level laser therapy for oral mucositis<sup><a href="#ref-32">32</a></sup>. However, most of these approaches have been studied only insufficiently (if at all) during ALL chemotherapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e494>Central neurotoxicity</h2><p class="" id=d252e497>Central nervous system (CNS) toxicities during treatment occur in 10% to 15% of patients with childhood ALL and cover a wide spectrum of syndromes with overlapping symptoms, including seizures<sup><a href="#ref-38">38</a></sup>, HD-MTX-related stroke-like syndrome (MTX-SLS)<sup><a href="#ref-39">39</a></sup> with or without reduced consciousness, posterior reversible encephalopathy syndrome (PRES)<sup><a href="#ref-40">40</a></sup>, and steroid psychosis<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>, and these may result in permanent or progressive neurocognitive defects (for example, attention, executive function)<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup> with or without white matter changes on magnetic resonance imaging (MRI).</p><p class="" id=d252e526>Corticosteroids frequently cause transient changes in sleep pattern, mood, and cognition, and this can be quite burdensome to both patients and parents<sup><a href="#ref-46">46</a></sup>. Corticosteroids may affect the neurotransmitters dopamine or serotonin, deregulate the hypothalamic-pituitary-adrenal (HPA) axis, and cause hippocampal injury<sup><a href="#ref-47">47</a></sup>. In general, the risk of acute, severe neurotoxicity cannot be predicted, but the risk is higher for children below six years and for treatment with dexamethasone compared with prednisolone, potentially reflecting higher CNS penetration and longer half-life in CNS of dexamethasone<sup><a href="#ref-48">48</a>–<a href="#ref-50">50</a></sup>. Germline DNA polymorphisms in genes related to drug disposition or neurogenesis or both have been associated with neurotoxicity<sup><a href="#ref-51">51</a></sup>, but these candidate gene associations remain to be validated.</p><p class="" id=d252e548>Seizures occur in approximately 10% of children with ALL<sup><a href="#ref-38">38</a></sup>. They can occur both as an isolated symptom, together with various other CNS toxicities (for example, intracranial hemorrhage or thrombosis, PRES, or MTX-SLS), or second to electrolyte and metabolic disturbances or to infections. Many patients subsequently require long-term anti-convulsive therapy, female sex being a significant risk factor<sup><a href="#ref-52">52</a></sup>.</p><p class="" id=d252e559>MTX-SLS, which is characterized by focal neurological deficits or hemiparesis and often accompanied by disturbances in speech, affect, or consciousness (or a combination of these), develops within two to three weeks (usually 2 to 14 days) after HD-MTX or intrathecal MTX administration and waxes and wanes over the subsequent hours to days and then resolves within a few days<sup><a href="#ref-39">39</a>,<a href="#ref-53">53</a></sup>. MTX interferes with the methionine/homocysteine pathway and purine <i>de novo</i> synthesis pathways, disrupts myelin, causes accumulation of homocysteine and adenosine, and influences neurotransmitter status with a strong excitatory effect on the <i>N</i>-methyl-D-aspartate receptor (NMDAR). Vitamin B<sub>12</sub> deficiency can promote these disturbances<sup><a href="#ref-54">54</a></sup>. The incidence of SLS varies from less than 1% to 15% in the literature and appears to vary according to the scheduling and intensity of MTX and co-administration of other agents such as cyclophosphamide and Ara-C and appears more frequently in children older than 10 years<sup><a href="#ref-39">39</a></sup>. Most patients make a full recovery, although there are reports of persisting neurological deficits, and the risk of recurrence with subsequent MTX therapy is low<sup><a href="#ref-39">39</a></sup>. Dextromethorphan, a non-competitive antagonist to NMDAR, or aminophylline (more relevant for acute MTX-induced neurotoxicity) has been advocated on the basis of small series<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. The effect may be dramatic, but the use of these interventions awaits formalized validation. MRI will not always be able to confirm MTX-SLS but often reveals characteristic changes allowing discrimination of MTX-SLS from PRES<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d252e603>PRES is a clinico-radiological entity frequently seen during the first months of ALL therapy, reflecting disturbances of cerebrovascular autoregulation and inconsistently characterized by headache, altered mental status, seizures, and visual disturbances<sup><a href="#ref-40">40</a>,<a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. It may have several causes, predominantly arterial hypertension, chemotherapy, and corticosteroids, but the exact cause can frequently not be determined in the individual patient<sup><a href="#ref-58">58</a></sup>. On cranial MRI, areas of vasogenic edema are predominant but not restricted to the posterior regions of the brain or being exclusively bilateral. Affected areas are hypointense on T1-weighted and hyperintense on T2-weighted MRI<sup><a href="#ref-59">59</a></sup>. In contrast to MTX-SLS, PRES is hyperintense on apparent diffusion-weighted coefficient MRI images.</p><p class="" id=d252e624>Some patients develop frank psychosis during corticosteroid therapy<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. There are no clear guidelines for their clinical management, but sleep medication and tranquilizers and, in severe cases, anti-psychotics (for example, risperidone) can be indicated<sup><a href="#ref-60">60</a></sup>.</p><p class="" id=d252e638>Transverse myelitis is a very rare complication seen in children with or without hematological malignancies<sup><a href="#ref-61">61</a></sup>. It may occasionally be associated with malignant infiltration<sup><a href="#ref-62">62</a></sup> but can also be seen as a result of intensive chemotherapy, and high-dose cytarabine, MTX, and vincristine have been suspected to play a role<sup><a href="#ref-63">63</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e656>Peripheral neuropathy</h2><p class="" id=d252e659>Peripheral motor or sensory neuropathy or both are common, usually caused by vincristine, and in general completely reversible but may require many months for improvement<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. In severe cases, they are occasionally associated with Charcot-Marie-Tooth disease<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>.</p><p class="" id=d252e676>Metabolic drug-drug interactions may enhance vincristine neurotoxicity<sup><a href="#ref-68">68</a></sup>. Vincristine is inactivated by the major drug-metabolizing CYP isoform in humans, CYP3A4, and the azoles ketoconazole, itraconazole, and posaconazole are potent inhibitors of CYP3A4<sup><a href="#ref-69">69</a></sup>. The potency of the azoles fluconazole and voriconazole as CYP3A4 inhibitors are much lower but may be clinically significant at high doses. A few germline DNA variants and gene expression profiles have been associated with the risk of vincristine-induced neuropathy<sup><a href="#ref-64">64</a>,<a href="#ref-70">70</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e698>Bone toxicities</h2><p class="" id=d252e701>The pathophysiology of osteoporosis during ALL therapy is uncertain, but the leukemia itself and the use of corticosteroids may cause osteoporosis and fractures, including multifocal compression fractures of the spine<sup><a href="#ref-71">71</a>–<a href="#ref-74">74</a></sup>, and osteoporosis affects up to 20% of newly diagnosed children with ALL<sup><a href="#ref-75">75</a></sup>. Five-year cumulative incidence of fractures has been reported to be 10% to 15% with no overall incidence difference between post-induction prednisolone or dexamethasone, although for adolescents dexamethasone seems to be associated with a higher risk<sup><a href="#ref-73">73</a>,<a href="#ref-76">76</a></sup>.</p><p class="" id=d252e722>The most severe skeletal complication is symptomatic ON, caused by bone death resulting from poor blood supply<sup><a href="#ref-77">77</a></sup>. The PTWG has published a consensus definition of ON that accounts for localization of ON, joint deformation and the impact of ON on symptoms and self-care<sup><a href="#ref-7">7</a></sup>. If routine MRI is performed, an even higher frequency of non-symptomatic ON will be detected<sup><a href="#ref-78">78</a></sup>. Thus, the overall reported frequency varies from less than 5% to more than 70%, and females and adolescents have the highest risk<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. ON is mainly diagnosed during the second year of ALL therapy (that is, during maintenance therapy), although presentation can occur earlier or even after cessation of therapy<sup><a href="#ref-78">78</a>,<a href="#ref-81">81</a></sup>. Hips and knees are most commonly affected in both subclinical and clinical cases, and often multiple joints are involved<sup><a href="#ref-77">77</a>,<a href="#ref-81">81</a></sup>. Many will suffer from daily pain, decreased ability of physical activity (or even need of a wheelchair), and reduced quality of life<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>. ON can lead to joint articular surface collapse with debilitating arthritis and need for joint-preserving or joint replacement surgery during the early phase of ON or months or years later.</p><p class="" id=d252e766>So far, the only proven preventive measure for ON is giving dexamethasone intermittently rather than continuously<sup><a href="#ref-79">79</a></sup>. Corticosteroids contribute to the development of ON through osseous lipocyte hypertrophy with resultant increased pressure within the bone, which can cause vascular collapse and necrosis, and corticosteroids can cause direct toxicity to osteocytes. Fat emboli, vasculitis, or microthromboemboli that cause vascular occlusion can also contribute. Accordingly, hyperlipidemia induced by corticosteroids and asparaginase has been suggested to be associated with increased risk of ON, although most studies have been inconclusive<sup><a href="#ref-78">78</a>,<a href="#ref-83">83</a></sup>.</p><p class="" id=d252e780>Genetic risk factors have been reported in pathways associated with the glutamate receptor, bone, lipid and folate metabolism, thymidylate synthase, corticosteroid disposition, and adipogenesis, but the associations have in general not been validated<sup><a href="#ref-78">78</a>,<a href="#ref-84">84</a>–<a href="#ref-86">86</a></sup>.</p><p class="" id=d252e794>The benefits of prognostication of ON by imaging await validation<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. Future research should focus on potential risk factors for various grades and for single-versus-multiple site ON, on the association with metabolism of drugs that may influence lipid profiles and coagulation<sup><a href="#ref-78">78</a></sup>, on the long-term outcome of ON, on improved guidelines for treatment adaptation and interventive surgery, and on the association of germline DNA variants with phenotype subsets.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e811>Thromboembolisms</h2><p class="" id=d252e814>TE located to the venous system is most common, and half of the cases involve the CNS<sup><a href="#ref-89">89</a>–<a href="#ref-91">91</a></sup>. The cumulative incidence of symptomatic venous TE is 2 to 8%<sup><a href="#ref-90">90</a>–<a href="#ref-93">93</a></sup>, but asymptomatic cases have been reported in up to 70% of patients<sup><a href="#ref-92">92</a>,<a href="#ref-94">94</a></sup>. Risk factors for TE include the leukemia itself, older age, central line catheters, immobilization, infections, systemic inflammation, and therapy with asparaginase or corticosteroids or both<sup><a href="#ref-76">76</a>,<a href="#ref-90">90</a>,<a href="#ref-93">93</a>,<a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>, whereas inherited thrombophilia risk factors, including common germline DNA polymorphisms, do not seem to play a role or at best remain uncertain<sup><a href="#ref-96">96</a></sup>. The fatality rate of venous TE is highest in children with thromboses in cerebral veins, and studies on the benefits of anti-thrombotic prophylaxis, preferably with the novel oral anti-coagulants, are needed<sup><a href="#ref-90">90</a>,<a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e872>Sinosoidal-obstruction syndrome</h2><p class="" id=d252e875>Until recently, SOS, previously known as veno-occlusive disease<sup><a href="#ref-90">99</a></sup>, has primarily been a serious complication of hSCT and is otherwise rare during childhood ALL therapy except with continuous oral thioguanine<sup><a href="#ref-100">100</a></sup>, not least in patients who carry low-activity alleles for thiopurin methyl transferase<sup><a href="#ref-101">101</a></sup>. Doppler ultrasound showing reversed hepatic portal flow may aid the diagnosis, but a normal flow does not exclude the diagnosis and thus is not a mandatory diagnostic requirement. Instead, at least three of five criteria need to be fulfilled: that is, hepatomegaly, hyperbilirubinemia above upper normal limit (UNL), ascites, weight gain at or above 5%, and thrombocytopenia (transfusion-resistant or otherwise unexplained by treatment or both)<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d252e894>The pathogenesis remains unclear, but drug-induced damage to hepatic endothelium and microcirculation and subsequent ischemic hepatocellular necrosis are the presumed mechanism<sup><a href="#ref-99">99</a>,<a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup>. Previously, SOS occurred extremely rarely during 6-MP therapy<sup><a href="#ref-100">100</a></sup> but recently has been described as a frequent complication to continuous polyethylene glycol-linked <i>Escherichia coli</i> asparaginase preparation (PEG-asparaginase) during 6-MP-based maintenance therapy when combined with pulses of either HD-MTX or vincristine/dexamethasone, probably reflecting the impact of asparaginase on 6-MP pharmacokinetics causing higher drug metabolite levels<sup><a href="#ref-104">104</a></sup>. Management of SOS during thiopurine therapy follows the same principles as management of SOS following hSCT: that is, fluid and sodium chloride restriction, diuretics, and, in the rare severe cases, defibrotide.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e921>Endocrinopathies</h2><p class="" id=d252e924>There is a paucity of prospective longitudinal studies determining endocrine changes during ALL therapy, and the existing studies have small sample sizes. Growth retardation and relative growth hormone deficiency are common during ALL therapy, but usually an adequate growth catch-up is obtained after cessation of therapy in children who do not receive radiotherapy<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>, but with a trend toward reduced final height<sup><a href="#ref-107">107</a></sup>.</p><p class="" id=d252e938>A significant weight gain is seen in up to 40% of children with ALL, primarily reflecting exposure to corticosteroids and reduced physical activity with insulin resistance, hyperglycemia, and prediabetes, which could indicate the need for dietary modifications and insulin therapy<sup><a href="#ref-108">108</a>–<a href="#ref-111">111</a></sup>. The risk of corticosteroid-induced hyperglycemia is aggravated by asparaginase therapy<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>. The prevalence of hyperglycemia during ALL therapy has been reported to be 10% to 20% during treatment with asparaginase and corticosteroids, most frequently in children above 10 years of age, with resolution after cessation or tapering down of these drugs<sup><a href="#ref-112">112</a>–<a href="#ref-116">116</a></sup>. Medication-induced diabetes may be a marker for metabolic disease later in life<sup><a href="#ref-116">116</a></sup>. Finally, hyperglycemia and obesity both have been associated with reduced event-free survival<sup><a href="#ref-117">117</a>,<a href="#ref-118">118</a></sup>.</p><p class="" id=d252e973>Fasting hypoglycemia is common during MTX/thiopurine-based maintenance therapy, especially in children below 6 years of age, but resolves after discontinuation of therapy<sup><a href="#ref-119">119</a>,<a href="#ref-120">120</a></sup>. It may reflect lowered plasma levels of the gluconeogenic amino acids (alanine and glutamine) as well as impaired glycogenolysis or glyconeogenesis<sup><a href="#ref-119">119</a>,<a href="#ref-121">121</a></sup>.</p><p class="" id=d252e990>Corticosteroids cause a suppression of the HPA axis with secondary adrenal insufficiency and impaired stress response in nearly all patients, which for some patients may last several months after cessation of corticosteroid therapy irrespective of whether prednisolone or dexamethasone has been used<sup><a href="#ref-122">122</a></sup>. It may be aggravated by co-administration of fluconazole<sup><a href="#ref-122">122</a></sup>. Thus, corticosteroid replacement is indicated during the first weeks to months after cessation of corticosteroid therapy, not least during episodes of serious stress unless a stimulation test has shown a normal adrenal response<sup><a href="#ref-122">122</a>,<a href="#ref-123">123</a></sup>. The duration of adrenal insufficiency has been ascribed to variants of the GR gene<sup><a href="#ref-124">124</a></sup>, but formal genome-wide association analyses are lacking.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1015>HD-MTX-related nephrotoxicity</h2><p class="" id=d252e1018>Alkalinization and vigorous hydration reduce the risk of significant nephrotoxicity with HD-MTX, but approximately 3% of patients will experience severe renal toxicity that will further compromise MTX clearance<sup><a href="#ref-125">125</a>–<a href="#ref-128">128</a></sup>. The nephrotoxicity is likely to be related to precipitation of MTX crystals in the kidneys and this is partly due to insufficient hydration and alkalization<sup><a href="#ref-129">129</a>,<a href="#ref-130">130</a></sup>. Plasma creatinine usually peaks within a few days after initiation of the HD-MTX infusion and returns to baseline after a few weeks. Nearly all patients will subsequently tolerate full-dose HD-MTX without recurrent nephrotoxicity<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>. Higher doses of folinic acid, adjusted by the plasma MTX levels, are essential to limit the risk of life-threatening myelosuppression and mucositis, but whether over-rescue could increase the risk of relapse remains an unsolved challenge<sup><a href="#ref-131">131</a>–<a href="#ref-133">133</a></sup>. In cases with extremely delayed MTX clearance, glucarpidase may be helpful to degrade MTX by enzymatic cleavage to 2,4-diamino-N10-methyl-pteroic acid (DAMPA) and glutamate<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>, but it does not promote restoration of renal function. Proton pump inhibitors and non-steroidal anti-inflammatory drugs<sup><a href="#ref-134">134</a>–<a href="#ref-142">142</a></sup> as well as foodstuff (for example, licorice<sup><a href="#ref-143">143</a></sup>) and beverages (with low pH or sweetened with licorice extract) have been suspected to affect the MTX clearance<sup><a href="#ref-144">144</a></sup>. Since the introduction of 5-HT3 receptor antagonists, emesis is not a problem during HD-MTX and not linked to acute kidney injury.</p><p class="" id=d252e1072>Trimethroprim-sulfamethoxazole used as <i>Pneumocystis jiroveci</i> prophylaxis during ALL therapy does not seem to interfere with HD-MTX PK<sup><a href="#ref-145">145</a></sup>.</p><p class="" id=d252e1082>Several germline DNA variants are associated with MTX clearance, most notably in <i>SLCO1B</i><sup><a href="#ref-146">146</a>–<a href="#ref-149">149</a></sup>, but none has yet been implemented in HD-MTX dosing strategies or been shown to be associated with extremely delayed MTX clearance.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1097>Toxicities secondary to asparaginase therapy</h2><p class="" id=d252e1100>Asparaginase causes a range of toxicities due to asparagine depletion and disturbed protein synthesis. These toxicities may occur in up to 20 to 25% of all patients<sup><a href="#ref-4">4</a></sup> and may lead to discontinuation of asparaginase therapy, which may increase the risk of relapse, not least in the CNS<sup><a href="#ref-150">150</a>,<a href="#ref-151">151</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1118>Asparaginase-associated allergy</h2><p class="" id=d252e1121>The various asparaginase preparations and recombinant analogs differ in their biologic half-lives (shortest for <i>Erwinia chrysanthemi</i>-derived asparaginase and longest for PEG-asparaginase) and in their immunogenicity (lowest for PEG-asparaginase)<sup><a href="#ref-152">152</a>,<a href="#ref-153">153</a></sup>. Asparaginase can induce antibody formation that neutralizes asparaginase with or without (so-called silent inactivation) clinical signs of hypersensitivity<sup><a href="#ref-154">154</a>–<a href="#ref-156">156</a></sup>. Identification of silent inactivation requires measurement of plasma asparaginase activity levels.</p><p class="" id=d252e1141>The reported frequency of allergic reactions ranges from 3 to 75% depending on the type, dose, route, and duration of asparaginase administration, and allergic reaction primarily occurs after the first or second dose and virtually always is associated with zero asparaginase activity<sup><a href="#ref-150">150</a>,<a href="#ref-154">154</a>,<a href="#ref-157">157</a>–<a href="#ref-162">162</a></sup>. The reactions range from mild, local reactions to life-threatening systemic responses, including urticaria, symptomatic bronchospasm, edema/angioedema, and hypotension. Premedication with corticosteroid and anti-histamines and increased infusion time can reduce allergic symptoms but do not prevent asparaginase inactivation, and thus symptoms of hypersensitivity indicate the need to switch from <i>E. coli</i>-derived preparations to Erwinia asparaginase (or vice versa)<sup><a href="#ref-7">7</a>,<a href="#ref-163">163</a></sup>. Less immunogenic asparaginase preparations are emerging but are not routinely used in first-line therapy<sup><a href="#ref-164">164</a>–<a href="#ref-166">166</a></sup>.</p><p class="" id=d252e1174>Allergic-like reactions (for example, vomiting, stomach ache, or rash) with intact asparaginase activity can be seen but do not indicate discontinuation of the drug<sup><a href="#ref-7">7</a></sup>. Therapeutic drug monitoring can be helpful for differentiating allergy and allergic-like reactions<sup><a href="#ref-154">154</a></sup>. HLA-DRB1*07:01 and genetic variations in <i>GRIA1</i> have been associated with a higher incidence of hypersensitivity and anti-asparaginase antibodies<sup><a href="#ref-167">167</a>,<a href="#ref-168">168</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1198>Asparaginase-associated pancreatitis</h2><p class="" id=d252e1201>Asparaginase-associated pancreatitis (AAP) has a reported incidence of 2 to 18% depending on the cumulative asparaginase dose (that is, treatment duration) and toxicity capture strategies but seemingly not on the route of administration<sup><a href="#ref-7">7</a>,<a href="#ref-158">158</a>,<a href="#ref-169">169</a>–<a href="#ref-174">174</a></sup>. AAP is most often diagnosed within two weeks of asparaginase exposure (median of 11 days with PEG-asparaginase), but the interval may be longer<sup><a href="#ref-175">175</a></sup>. The diagnostic criteria defined by the PTWG<sup><a href="#ref-7">7</a></sup> are similar to those developed for pancreatitis in general<sup><a href="#ref-176">176</a></sup> and require two of three criteria to be met: (i) abdominal symptoms suggestive of AAP, (ii) characteristic findings of pancreatitis on imaging, and (iii) serum lipase or amylase or both at least three times the UNL, and both enzymes should be measured because of a poor correlation between the two<sup><a href="#ref-175">175</a></sup>. If imaging shows pancreatic necrosis or hemorrhage and/or the abdomimal symptoms and elevated pancreatic enzymes at least three times the UNL persist for more than 72 hours, AAP is classified as severe and otherwise as mild.</p><p class="" id=d252e1233>Most AAP episodes are accompanied by systemic inflammatory responses (fever, elevated heart rate, elevated respiratory rate, or hypotension) and thus may easily be misinterpreted as sepsis. In addition to transient or permanent discontinuation of asparaginase therapy, treatment of AAP includes appropriate triage, fluid resuscitation, antibiotics (until an infection is ruled out), and monitoring for and treatment of AAP-related complications<sup><a href="#ref-177">177</a></sup>. The mortality rate is low, but patients systemically affected at AAP diagnosis are at increased risk of developing pseudocysts, acute or persistent diabetes mellitus, and chronic/relapsing pancreatitis<sup><a href="#ref-175">175</a>,<a href="#ref-178">178</a></sup>. Octreotide has been tested in few patients, but the benefit thereof remains to be determined<sup><a href="#ref-179">179</a>,<a href="#ref-180">180</a></sup>.</p><p class="" id=d252e1254>The risk of a second AAP after re-exposing patients with AAP to asparaginase is almost 50% and does not seem to be significantly lower if the first AAP episode was classified as mild<sup><a href="#ref-170">170</a>,<a href="#ref-174">174</a>,<a href="#ref-175">175</a></sup>.</p><p class="" id=d252e1267>Risk factors for AAP are few, although the incidence is associated with older age. Polymorphisms in <i>PRSS1</i>, <i>SPINK1</i>, <i>ASNS</i>, <i>ULK2</i>, <i>RGS6</i>, and <i>CPA2</i> genes have been associated either with pediatric pancreatitis in general or with AAP<sup><a href="#ref-162">162</a>,<a href="#ref-174">174</a>,<a href="#ref-181">181</a>,<a href="#ref-182">182</a></sup>, although these associations await validation.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1305>Hyperlipidemia</h2><p class="" id=d252e1308>Elevated triglycerides and cholesterol occur frequently during ALL therapy and are associated with corticosteroid and asparaginase therapy<sup><a href="#ref-7">7</a>,<a href="#ref-78">78</a>,<a href="#ref-83">83</a>,<a href="#ref-183">183</a></sup>. However, patients are generally completely unaffected, even when levels are 40 to 50 times the UNL, the association with specific toxicities is very uncertain, and accordingly neither routine measurements nor interventions are recommended<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d252e1328>The hypertriglyceridemia is likely related to an increase in the endogenous hepatic synthesis of very low-density lipoprotein combined with a decreased activity in lipoprotein lipase, an enzyme involved in the removal of triglyceride-rich lipoproteins from the plasma<sup><a href="#ref-184">184</a></sup>.</p><p class="" id=d252e1335>The most common preventive measures in cases of hypertriglyceridemia are dietary restrictions (very limited effect), fibrates, insulin infusions, heparin infusions, and in extreme cases plasmapheresis, but there are no data to support that any of these interventions reduces the risk of hypertriglyceridemia-associated toxicities<sup><a href="#ref-83">83</a>,<a href="#ref-185">185</a>–<a href="#ref-189">189</a></sup>. In adults with non-malignant disorders, hypertriglyceridemia (above 10 times the UNL) has been associated with an increased risk of acute pancreatitis<sup><a href="#ref-185">185</a>,<a href="#ref-188">188</a>,<a href="#ref-190">190</a></sup>, but so far this has not been replicated in children with ALL<sup><a href="#ref-191">191</a></sup>. A few studies have indicated associations with development of ON and thrombosis<sup><a href="#ref-78">78</a>,<a href="#ref-83">83</a>,<a href="#ref-95">95</a>,<a href="#ref-158">158</a>,<a href="#ref-188">188</a>,<a href="#ref-192">192</a></sup>, but no randomized studies have explored whether lipid-lowering interventions prevent these complications.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1384>Host genome variant associations</h2><p class="" id=d252e1387>As mentioned above, multiple variants in germline DNA have been associated with the pharmacology of anti-leukemic agents, including the risk of toxicities<sup><a href="#ref-6">6</a>,<a href="#ref-68">68</a>,<a href="#ref-193">193</a></sup>, but their individual hazard ratios are generally low (&lt;2.0), the variants are rare or lack validation in independent studies, and treatment alterations according to such variants so far have not been implemented in childhood ALL therapy. The main reasons for our current inability to identify clinically actionable germline variants associated with specific toxicities are lack of sufficient study power (since each toxicity is rare and few trial groups are investigating genotype variation), incomplete toxicity capture, lack of detailed phenotyping (for example, lumping all subtypes and grades of a toxicity), and exploration of single-nucleotide polymorphisms rather than biological pathways. To address these limitations, the PTWG is now collecting phenotypes of several acute toxicities (pancreatitis, ON, and CNS toxicities) in hundreds of patients for each of these toxicities to associate detailed phenotypes with germline DNA variants<sup><a href="#ref-175">175</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1407>Leukemia predisposition syndromes</h2><p class="" id=d252e1410>Recent research has identified several germline mutations in genes that play a critical role in hematopoiesis and lymphoid development and that are also frequently somatically mutated in ALL, such as <i>PAX5</i><sup><a href="#ref-194">194</a>,<a href="#ref-195">195</a></sup>, <i>ETV6</i><sup><a href="#ref-196">196</a>,<a href="#ref-197">197</a></sup>, <i>RUNX11</i><sup><a href="#ref-198">198</a></sup>, and <i>IKZF1</i><sup><a href="#ref-199">199</a></sup>, which align with the findings of high subtype concordance in familial cases of ALL<sup><a href="#ref-195">195</a>,<a href="#ref-197">197</a>,<a href="#ref-200">200</a>,<a href="#ref-201">201</a></sup>. This indicates that pure familial ALL syndromes may constitute a substantial part of ALL etiology and that more such syndromes are expected to emerge in parallel with a growing number of patients being germline-sequenced and with a deeper understanding of the impact of coding and non-coding DNA interactions<sup><a href="#ref-196">196</a></sup>. However, the impact of such germline DNA mutations on toxicities, not least those involving the bone marrow and immune system, remains to be determined. The risk of second malignant neoplasms may also be increased when childhood ALL arises due to a predisposition syndrome. Unusual acute toxicities and second malignant neoplasms therefore should lead to clinical suspicion of an underlying syndrome<sup><a href="#ref-202">202</a></sup>.</p><p class="" id=d252e1465>Down syndrome is the most frequent known germline mutation predisposing to ALL and is associated with enhanced gastrointestinal toxicity<sup><a href="#ref-203">203</a></sup>. However, reducing treatment intensity may also increase the risk of relapse<sup><a href="#ref-204">204</a></sup> and should be considered only in case of excessive toxicity in the 10 to 15% of Down syndrome-ALL patients who harbor high hyperdiploidy or an <i>ETV6-RUNX1</i> translocation, since these subsets have a superior cure rate<sup><a href="#ref-205">205</a></sup>.</p><p class="" id=d252e1483>Several other ALL-predisposing syndromes such as Li-Fraumeni, ataxia telangiectasia, Nijmegen breakage, biallelic mismatch repair, and Fanconi anemia can also exhibit syndrome-related toxicities when exposed to DNA-damaging anti-cancer agents or radiotherapy<sup><a href="#ref-206">206</a>–<a href="#ref-209">209</a></sup>. In such cases, a reduction of DNA-damaging drug doses must be considered on an individual basis, and at least for ataxia telangiectasia and Nijmegen breakage dose reduction may not be associated with an increased risk of relapse<sup><a href="#ref-210">210</a></sup>. In contrast, thiopurine-based maintenance therapy may be less efficient in patients with biallelic mismatch repair deficiency, since this pathway is critical for thiopurine cytotoxicity<sup><a href="#ref-211">211</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1504>Future research</h2><p class="" id=d252e1507>The low frequency and poor definitions of most of the listed organ toxicities have hampered their in-depth exploration, including the impact of specific drug dosing regimens, and identification of clear risk factors for certain phenotypic subsets. The recent PTWG consensus definitions of 14 of these toxicities have provided a platform for international collaboration on these issues<sup><a href="#ref-7">7</a></sup>. The results from the first of such explorations demonstrate its feasibility<sup><a href="#ref-175">175</a></sup> and may allow exploration of the association between risk factors, including host DNA variants, in well-defined phenotypic subsets and provide evidence-based guidelines for treatment adaptation. Furthermore, the association of these acute toxicities with the risk of long-term organ toxicities (for example, dementia, diabetes, arthrosis, and chronic pancreatitis) remains to be mapped. Currently, event-free survival measures encompass death during induction, resistance to first-line therapy, relapse of leukemia, non-leukemic death during clinical remission, and development of a second cancer. However, many patients with a late relapse or a second cancer have a fair chance of cure<sup><a href="#ref-212">212</a>,<a href="#ref-213">213</a></sup>, whereas chronic toxicities are generally irreversible and challenge patients’ ability to live a normal adult life<sup><a href="#ref-214">214</a></sup>. This calls for new endpoint measures that include both survival and quality of life, which will require common strategies for toxicity capture and registration, and international collaboration to identify host genome variants and exposures (for example, anti-leukemic treatment, co-medication, and diet) associated with the risk of specific toxicities, but it also demands the development of a joint endpoint scoring system that encompasses OS as well as severe toxicities, both acute and long-term.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d252e1533>Abbreviations</h2><p class="" id=d252e1536>6-MP, 6-mercaptopurine; AAP, asparaginase-associated pancreatitis; ALL, acute lymphoblastic leukemia; CNS, central nervous system; HD, high dose; HPA, hypothalamic-pituitary-adrenal; hSCT, hematopoietic stem cell transplantation; MRI, magnetic resonance imaging; MTX, methotrexate; NMDAR, N-methyl-D-aspartate receptor ON, osteonecrosis; OS, overall survival; PEG, polyethylene glycol; PRES, posterior reversible encephalopathy syndrome; PTWG, Ponte di Legno Toxicity Working Group; SLS, stroke-like syndrome; SOS, sinusoidal obstruction syndrome; TE, thromboembolism; UNL, upper normal limit.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d252e1 class=n-a></a><h2 class=main-title id=d888>Competing interests</h2><p class=metadata-entry><a name=d252e209 class=n-a></a><p id=d252e211> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d252e1 class=n-a></a><h2 class=main-title id=d890>Grant information</h2><p>This work was supported by the Danish Cancer Society and the Danish Childhood Cancer Foundation.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d252e1543 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1585>References</h2><div class="section ref-list"><a name=d252e1543 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d252e1550 class=n-a></a>Starý J, Hrušák O: Recent advances in the management of pediatric acute lymphoblastic leukemia [version 1; referees: 2 approved]. <i>F1000Res.</i> 2016; <b>5</b>(F1000 Faculty Rev): 2635. <a target=xrefwindow id=d252e1558 href="http://dx.doi.org/10.12688/f1000research.9548.1">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d252e1567 class=n-a></a>Pui CH, Yang JJ, Hunger SP, <i> et al.</i>: Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <i>J Clin Oncol.</i> 2015; <b>33</b>(27): 2938–48. <a target=xrefwindow id=d252e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/26304874">PubMed Abstract </a> | <a target=xrefwindow id=d252e1581 href="http://dx.doi.org/10.1200/JCO.2014.59.1636">Publisher Full Text </a> | <a target=xrefwindow id=d252e1585 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4567699">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d252e1594 class=n-a></a>Lund B, Åsberg A, Heyman M, <i> et al.</i>: Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. <i>Pediatr Blood Cancer.</i> 2011; <b>56</b>(4): 551–9. <a target=xrefwindow id=d252e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/21298739">PubMed Abstract </a> | <a target=xrefwindow id=d252e1608 href="http://dx.doi.org/10.1002/pbc.22719">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d252e1617 class=n-a></a>Frandsen TL, Heyman M, Abrahamsson J, <i> et al.</i>: Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. <i>Eur J Cancer.</i> 2014; <b>50</b>(2): 251–9. <a target=xrefwindow id=d252e1628 href="http://www.ncbi.nlm.nih.gov/pubmed/24231337">PubMed Abstract </a> | <a target=xrefwindow id=d252e1631 href="http://dx.doi.org/10.1016/j.ejca.2013.09.027">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d252e1640 class=n-a></a>Mullighan CG: The molecular genetic makeup of acute lymphoblastic leukemia. <i>Hematology Am Soc Hematol Educ Program.</i> 2012; <b>2012</b>: 389–96. <a target=xrefwindow id=d252e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/23233609">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d252e1658 class=n-a></a>Moriyama T, Relling MV, Yang JJ: Inherited genetic variation in childhood acute lymphoblastic leukemia. <i>Blood.</i> 2015; <b>125</b>(26): 3988–95. <a target=xrefwindow id=d252e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/25999454">PubMed Abstract </a> | <a target=xrefwindow id=d252e1669 href="http://dx.doi.org/10.1182/blood-2014-12-580001">Publisher Full Text </a> | <a target=xrefwindow id=d252e1672 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4481591">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d252e1681 class=n-a></a>Schmiegelow K, Attarbaschi A, Barzilai S, <i> et al.</i>: Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): e231–9. <a target=xrefwindow id=d252e1692 href="http://www.ncbi.nlm.nih.gov/pubmed/27299279">PubMed Abstract </a> | <a target=xrefwindow id=d252e1695 href="http://dx.doi.org/10.1016/S1470-2045(16)30035-3">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d252e1704 class=n-a></a>National Institutes of Health: Common Terminology Criteria for Adverse Events (CTCAE). 2009; (v4.03: June 14, 2010). <a target=xrefwindow id=d252e1706 href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf">Reference Source</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d252e1715 class=n-a></a>de Rojas T, Bautista FJ, Madero L, <i> et al.</i>: The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children. <i>J Clin Oncol.</i> 2016; <b>34</b>(18): 2196–7. <a target=xrefwindow id=d252e1726 href="http://www.ncbi.nlm.nih.gov/pubmed/27114600">PubMed Abstract </a> | <a target=xrefwindow id=d252e1729 href="http://dx.doi.org/10.1200/JCO.2016.67.7104">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d252e1738 class=n-a></a>Rask C, Albertioni F, Schrøder H, <i> et al.</i>: Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate. <i>Pediatr Hematol Oncol.</i> 1996; <b>13</b>(4): 359–67. <a target=xrefwindow id=d252e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/8837142">PubMed Abstract </a> | <a target=xrefwindow id=d252e1752 href="http://dx.doi.org/10.3109/08880019609030842">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d252e1761 class=n-a></a>Figliolia SL, Oliveira DT, Pereira MC, <i> et al.</i>: Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. <i>Oral Dis.</i> 2008; <b>14</b>(8): 761–6. <a target=xrefwindow id=d252e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/18761642">PubMed Abstract </a> | <a target=xrefwindow id=d252e1775 href="http://dx.doi.org/10.1111/j.1601-0825.2008.01468.x">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d252e1785 class=n-a></a>Otmani N, Alami R, Hessissen L, <i> et al.</i>: Determinants of severe oral mucositis in paediatric cancer patients: a prospective study. <i>Int J Paediatr Dent.</i> 2011; <b>21</b>(3): 210–6. <a target=xrefwindow id=d252e1796 href="http://www.ncbi.nlm.nih.gov/pubmed/21362073">PubMed Abstract </a> | <a target=xrefwindow id=d252e1799 href="http://dx.doi.org/10.1111/j.1365-263X.2011.01113.x">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d252e1808 class=n-a></a>Rathe M, Sorensen GL, Wehner PS, <i> et al.</i>: Chemotherapeutic treatment reduces circulating levels of surfactant protein-D in children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2017; <b>64</b>(3): e26253. <a target=xrefwindow id=d252e1819 href="http://www.ncbi.nlm.nih.gov/pubmed/27667327">PubMed Abstract </a> | <a target=xrefwindow id=d252e1822 href="http://dx.doi.org/10.1002/pbc.26253">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d252e1831 class=n-a></a>Cheng KK, Goggins WB, Lee VW, <i> et al.</i>: Risk factors for oral mucositis in children undergoing chemotherapy: a matched case-control study. <i>Oral Oncol.</i> 2008; <b>44</b>(11): 1019–25. <a target=xrefwindow id=d252e1842 href="http://www.ncbi.nlm.nih.gov/pubmed/18329325">PubMed Abstract </a> | <a target=xrefwindow id=d252e1845 href="http://dx.doi.org/10.1016/j.oraloncology.2008.01.003">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d252e1854 class=n-a></a>Ye Y, Carlsson G, Agholme MB, <i> et al.</i>: Pretherapeutic plasma pro- and anti- inflammatory mediators are related to high risk of oral mucositis in pediatric patients with acute leukemia: a prospective cohort study. <i>PLoS One.</i> 2013; <b>8</b>(5): e64918. <a target=xrefwindow id=d252e1865 href="http://www.ncbi.nlm.nih.gov/pubmed/23741421">PubMed Abstract </a> | <a target=xrefwindow id=d252e1868 href="http://dx.doi.org/10.1371/journal.pone.0064918">Publisher Full Text </a> | <a target=xrefwindow id=d252e1872 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3669020">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d252e1881 class=n-a></a>Yang L, Hu X, Xu L: Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. <i>Tumour Biol.</i> 2012; <b>33</b>(5): 1445–54. <a target=xrefwindow id=d252e1889 href="http://www.ncbi.nlm.nih.gov/pubmed/22528943">PubMed Abstract </a> | <a target=xrefwindow id=d252e1892 href="http://dx.doi.org/10.1007/s13277-012-0395-2">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d252e1901 class=n-a></a>Ozdemir N, Celkan T, Barış S, <i> et al.</i>: DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma. <i>Leuk Res.</i> 2012; <b>36</b>(5): 565–9. <a target=xrefwindow id=d252e1912 href="http://www.ncbi.nlm.nih.gov/pubmed/22047709">PubMed Abstract </a> | <a target=xrefwindow id=d252e1915 href="http://dx.doi.org/10.1016/j.leukres.2011.10.012">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d252e1925 class=n-a></a>Kuiken NS, Rings EH, Tissing WJ: Risk analysis, diagnosis and management of gastrointestinal mucositis in pediatric cancer patients. <i>Crit Rev Oncol Hematol.</i> 2015; <b>94</b>(1): 87–97. <a target=xrefwindow id=d252e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/25560731">PubMed Abstract </a> | <a target=xrefwindow id=d252e1936 href="http://dx.doi.org/10.1016/j.critrevonc.2014.12.009">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d252e1945 class=n-a></a>Sonis ST: The pathobiology of mucositis. <i>Nat Rev Cancer.</i> 2004; <b>4</b>(4): 277–84. <a target=xrefwindow id=d252e1953 href="http://www.ncbi.nlm.nih.gov/pubmed/15057287">PubMed Abstract </a> | <a target=xrefwindow id=d252e1956 href="http://dx.doi.org/10.1038/nrc1318">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d252e1965 class=n-a></a>Sonis ST: Pathobiology of oral mucositis: novel insights and opportunities. <i>J Support Oncol.</i> 2007; <b>5</b>(9 Suppl 4): 3–11. <a target=xrefwindow id=d252e1973 href="http://www.ncbi.nlm.nih.gov/pubmed/18046993">PubMed Abstract </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d252e1982 class=n-a></a>Kornblit B, Müller K: Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplant.</i> 2016. <a target=xrefwindow id=d252e1987 href="http://www.ncbi.nlm.nih.gov/pubmed/27941769">PubMed Abstract </a> | <a target=xrefwindow id=d252e1990 href="http://dx.doi.org/10.1038/bmt.2016.263">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d252e1999 class=n-a></a>van Vliet MJ, Harmsen HJ, de Bont ES, <i> et al.</i>: The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. <i>PLoS Pathog.</i> 2010; <b>6</b>(5): e1000879. <a target=xrefwindow id=d252e2010 href="http://www.ncbi.nlm.nih.gov/pubmed/20523891">PubMed Abstract </a> | <a target=xrefwindow id=d252e2013 href="http://dx.doi.org/10.1371/journal.ppat.1000879">Publisher Full Text </a> | <a target=xrefwindow id=d252e2017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2877735">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d252e2026 class=n-a></a>Fijlstra M, Ferdous M, Koning AM, <i> et al.</i>: Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. <i>Support Care Cancer.</i> 2015; <b>23</b>(6): 1513–22. <a target=xrefwindow id=d252e2037 href="http://www.ncbi.nlm.nih.gov/pubmed/25376667">PubMed Abstract </a> | <a target=xrefwindow id=d252e2040 href="http://dx.doi.org/10.1007/s00520-014-2487-6">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d252e2050 class=n-a></a>Herbers AH, de Haan AF, van der Velden WJ, <i> et al.</i>: Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. <i>Transpl Infect Dis.</i> 2014; <b>16</b>(2): 279–85. <a target=xrefwindow id=d252e2061 href="http://www.ncbi.nlm.nih.gov/pubmed/24621081">PubMed Abstract </a> | <a target=xrefwindow id=d252e2064 href="http://dx.doi.org/10.1111/tid.12195">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d252e2073 class=n-a></a>Bakhshi S, Padmanjali KS, Arya LS: Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. <i>Pediatr Hematol Oncol.</i> 2008; <b>25</b>(5): 385–92. <a target=xrefwindow id=d252e2081 href="http://www.ncbi.nlm.nih.gov/pubmed/18569840">PubMed Abstract </a> | <a target=xrefwindow id=d252e2084 href="http://dx.doi.org/10.1080/08880010802106564">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d252e2093 class=n-a></a>Stabell N, Nordal E, Stensvold E, <i> et al.</i>: Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. <i>Scand J Infect Dis.</i> 2008; <b>40</b>(4): 301–7. <a target=xrefwindow id=d252e2104 href="http://www.ncbi.nlm.nih.gov/pubmed/17918015">PubMed Abstract </a> | <a target=xrefwindow id=d252e2107 href="http://dx.doi.org/10.1080/00365540701670436">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d252e2116 class=n-a></a>Blijlevens NM, Donnelly JP, DePauw BE: Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. <i>Bone Marrow Transplant.</i> 2005; <b>36</b>(8): 703–7. <a target=xrefwindow id=d252e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/16062174">PubMed Abstract </a> | <a target=xrefwindow id=d252e2127 href="http://dx.doi.org/10.1038/sj.bmt.1705118">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d252e2136 class=n-a></a>van der Velden WJ, Blijlevens NM, Feuth T, <i> et al.</i>: Febrile mucositis in haematopoietic SCT recipients. <i>Bone Marrow Transplant.</i> 2009; <b>43</b>(1): 55–60. <a target=xrefwindow id=d252e2147 href="http://www.ncbi.nlm.nih.gov/pubmed/18762766">PubMed Abstract </a> | <a target=xrefwindow id=d252e2150 href="http://dx.doi.org/10.1038/bmt.2008.270">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d252e2159 class=n-a></a>Pontoppidan PL, Jordan K, Carlsen AL, <i> et al.</i>: Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation. <i>Int Immunopharmacol.</i> 2015; <b>25</b>(1): 180–8. <a target=xrefwindow id=d252e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/25614225">PubMed Abstract </a> | <a target=xrefwindow id=d252e2173 href="http://dx.doi.org/10.1016/j.intimp.2014.12.038">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d252e2183 class=n-a></a>Schots R, van Riet I, Othman TB, <i> et al.</i>: An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. <i>Bone Marrow Transplant.</i> 2002; <b>30</b>(7): 441–6. <a target=xrefwindow id=d252e2194 href="http://www.ncbi.nlm.nih.gov/pubmed/12368956">PubMed Abstract </a> | <a target=xrefwindow id=d252e2197 href="http://dx.doi.org/10.1038/sj.bmt.1703672">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d252e2206 class=n-a></a>McNeer JL, Kletzel M, Rademaker A, <i> et al.</i>: Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation. <i>Biol Blood Marrow Transplant.</i> 2010; <b>16</b>(3): 350–7. <a target=xrefwindow id=d252e2217 href="http://www.ncbi.nlm.nih.gov/pubmed/20005964">PubMed Abstract </a> | <a target=xrefwindow id=d252e2220 href="http://dx.doi.org/10.1016/j.bbmt.2009.10.036">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d252e2229 class=n-a></a>Gibson RJ, Keefe DM, Lalla RV, <i> et al.</i>: Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. <i>Support Care Cancer.</i> 2013; <b>21</b>(1): 313–26. <a target=xrefwindow id=d252e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/23142924">PubMed Abstract </a> | <a target=xrefwindow id=d252e2243 href="http://dx.doi.org/10.1007/s00520-012-1644-z">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d252e2252 class=n-a></a>White MC, Hommers C, Parry S, <i> et al.</i>: Pain management in 100 episodes of severe mucositis in children. <i>Paediatr Anaesth.</i> 2011; <b>21</b>(4): 411–6. <a target=xrefwindow id=d252e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/21251145">PubMed Abstract </a> | <a target=xrefwindow id=d252e2266 href="http://dx.doi.org/10.1111/j.1460-9592.2010.03515.x">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d252e2275 class=n-a></a>Urbancsek H, Kazar T, Mezes I, <i> et al.</i>: Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. <i>Eur J Gastroenterol Hepatol.</i> 2001; <b>13</b>(4): 391–6. <a target=xrefwindow id=d252e2286 href="http://www.ncbi.nlm.nih.gov/pubmed/11338068">PubMed Abstract </a> | <a target=xrefwindow id=d252e2289 href="http://dx.doi.org/10.1097/00042737-200104000-00015">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d252e2298 class=n-a></a>Delia P, Sansotta G, Donato V, <i> et al.</i>: Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. <i>Am J Gastroenterol.</i> 2002; <b>97</b>(8): 2150–2. <a target=xrefwindow id=d252e2309 href="http://www.ncbi.nlm.nih.gov/pubmed/12190202">PubMed Abstract </a> | <a target=xrefwindow id=d252e2312 href="http://dx.doi.org/10.1111/j.1572-0241.2002.05946.x">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d252e2322 class=n-a></a>Osterlund P, Ruotsalainen T, Korpela R, <i> et al.</i>: <i>Lactobacillus</i> supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. <i>Br J Cancer.</i> 2007; <b>97</b>(8): 1028–34. <a target=xrefwindow id=d252e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/17895895">PubMed Abstract </a> | <a target=xrefwindow id=d252e2340 href="http://dx.doi.org/10.1038/sj.bjc.6603990">Publisher Full Text </a> | <a target=xrefwindow id=d252e2343 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2360429">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d252e2352 class=n-a></a>S&amp;D Pharma SK s.r.o: Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients (FENSY). NCT02544685. <a target=xrefwindow id=d252e2354 href="https://clinicaltrials.gov/ct2/show/NCT02544685">Reference Source</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d252e2363 class=n-a></a>Ochs JJ, Bowman WP, Pui CH, <i> et al.</i>: Seizures in childhood lymphoblastic leukaemia patients. <i>Lancet.</i> 1984; <b>2</b>(8417–8418): 1422–4. <a target=xrefwindow id=d252e2374 href="http://www.ncbi.nlm.nih.gov/pubmed/6151043">PubMed Abstract </a> | <a target=xrefwindow id=d252e2377 href="http://dx.doi.org/10.1016/S0140-6736(84)91621-0">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d252e2386 class=n-a></a>Bond J, Hough R, Moppett J, <i> et al.</i>: 'Stroke-like syndrome' caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial. <i>Leukemia.</i> 2013; <b>27</b>(4): 954–6. <a target=xrefwindow id=d252e2397 href="http://www.ncbi.nlm.nih.gov/pubmed/23149600">PubMed Abstract </a> | <a target=xrefwindow id=d252e2400 href="http://dx.doi.org/10.1038/leu.2012.328">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d252e2409 class=n-a></a>de Laat P, Te Winkel ML, Devos AS, <i> et al.</i>: Posterior reversible encephalopathy syndrome in childhood cancer. <i>Ann Oncol.</i> 2011; <b>22</b>(2): 472–8. <a target=xrefwindow id=d252e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/20699277">PubMed Abstract </a> | <a target=xrefwindow id=d252e2423 href="http://dx.doi.org/10.1093/annonc/mdq382">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d252e2432 class=n-a></a>Judd LL, Schettler PJ, Brown ES, <i> et al.</i>: Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. <i>Am J Psychiatry.</i> 2014; <b>171</b>(10): 1045–51. <a target=xrefwindow id=d252e2443 href="http://www.ncbi.nlm.nih.gov/pubmed/25272344">PubMed Abstract </a> | <a target=xrefwindow id=d252e2446 href="http://dx.doi.org/10.1176/appi.ajp.2014.13091264">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d252e2456 class=n-a></a>Drozdowicz LB, Bostwick JM: Psychiatric adverse effects of pediatric corticosteroid use. <i>Mayo Clin Proc.</i> 2014; <b>89</b>(6): 817–34. <a target=xrefwindow id=d252e2464 href="http://www.ncbi.nlm.nih.gov/pubmed/24943696">PubMed Abstract </a> | <a target=xrefwindow id=d252e2467 href="http://dx.doi.org/10.1016/j.mayocp.2014.01.010">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d252e2476 class=n-a></a>Waber DP, Carpentieri SC, Klar N, <i> et al.</i>: Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. <i>J Pediatr Hematol Oncol.</i> 2000; <b>22</b>(3): 206–13. <a target=xrefwindow id=d252e2487 href="http://www.ncbi.nlm.nih.gov/pubmed/10864051">PubMed Abstract </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d252e2496 class=n-a></a>Waber DP, McCabe M, Sebree M, <i> et al.</i>: Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(11): 1785–91. <a target=xrefwindow id=d252e2507 href="http://www.ncbi.nlm.nih.gov/pubmed/23832430">PubMed Abstract </a> | <a target=xrefwindow id=d252e2510 href="http://dx.doi.org/10.1002/pbc.24666">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d252e2519 class=n-a></a>Halsey C, Buck G, Richards S, <i> et al.</i>: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. <i>J Hematol Oncol.</i> 2011; <b>4</b>: 42. <a target=xrefwindow id=d252e2530 href="http://www.ncbi.nlm.nih.gov/pubmed/21996369">PubMed Abstract </a> | <a target=xrefwindow id=d252e2533 href="http://dx.doi.org/10.1186/1756-8722-4-42">Publisher Full Text </a> | <a target=xrefwindow id=d252e2537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3219592">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d252e2546 class=n-a></a>McGrath P, Holewa H: The emotional consequences of corticosteroid use in hematology: preliminary findings. <i>J Psychosoc Oncol.</i> 2010; <b>28</b>(4): 335–50. <a target=xrefwindow id=d252e2554 href="http://www.ncbi.nlm.nih.gov/pubmed/20623411">PubMed Abstract </a> | <a target=xrefwindow id=d252e2557 href="http://dx.doi.org/10.1080/07347332.2010.485246">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d252e2566 class=n-a></a>Stuart FA, Segal TY, Keady S: Adverse psychological effects of corticosteroids in children and adolescents. <i>Arch Dis Child.</i> 2005; <b>90</b>(5): 500–6. <a target=xrefwindow id=d252e2574 href="http://www.ncbi.nlm.nih.gov/pubmed/15851433">PubMed Abstract </a> | <a target=xrefwindow id=d252e2577 href="http://dx.doi.org/10.1136/adc.2003.041541">Publisher Full Text </a> | <a target=xrefwindow id=d252e2580 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1720409">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d252e2590 class=n-a></a>Balis FM, Lester CM, Chrousos GP, <i> et al.</i>: Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. <i>J Clin Oncol.</i> 1987; <b>5</b>(2): 202–7. <a target=xrefwindow id=d252e2601 href="http://www.ncbi.nlm.nih.gov/pubmed/3806166">PubMed Abstract </a> | <a target=xrefwindow id=d252e2604 href="http://dx.doi.org/10.1200/JCO.1987.5.2.202">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d252e2613 class=n-a></a>Mrakotsky CM, Silverman LB, Dahlberg SE, <i> et al.</i>: Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Pediatr Blood Cancer.</i> 2011; <b>57</b>(3): 492–8. <a target=xrefwindow id=d252e2624 href="http://www.ncbi.nlm.nih.gov/pubmed/21560226">PubMed Abstract </a> | <a target=xrefwindow id=d252e2627 href="http://dx.doi.org/10.1002/pbc.23060">Publisher Full Text </a> | <a target=xrefwindow id=d252e2631 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3354622">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d252e2640 class=n-a></a>Teuffel O, Kuster SP, Hunger SP, <i> et al.</i>: Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. <i>Leukemia.</i> 2011; <b>25</b>(8): 1232–8. <a target=xrefwindow id=d252e2651 href="http://www.ncbi.nlm.nih.gov/pubmed/21527934">PubMed Abstract </a> | <a target=xrefwindow id=d252e2654 href="http://dx.doi.org/10.1038/leu.2011.84">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718281717"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e2663 class=n-a></a>Bhojwani D, Sabin ND, Pei D, <i> et al.</i>: Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2014; <b>32</b>(9): 949–59. <a target=xrefwindow id=d252e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/24550419">PubMed Abstract </a> | <a target=xrefwindow id=d252e2677 href="http://dx.doi.org/10.1200/JCO.2013.53.0808">Publisher Full Text </a> | <a target=xrefwindow id=d252e2681 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3948096">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718281717">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d252e2694 class=n-a></a>Khan RB, Morris EB, Pui CH, <i> et al.</i>: Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies. <i>J Child Neurol.</i> 2014; <b>29</b>(6): 774–81. <a target=xrefwindow id=d252e2705 href="http://www.ncbi.nlm.nih.gov/pubmed/23666043">PubMed Abstract </a> | <a target=xrefwindow id=d252e2708 href="http://dx.doi.org/10.1177/0883073813488675">Publisher Full Text </a> | <a target=xrefwindow id=d252e2712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4207712">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d252e2721 class=n-a></a>Rubnitz JE, Relling MV, Harrison PL, <i> et al.</i>: Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. <i>Leukemia.</i> 1998; <b>12</b>(8): 1176–81. <a target=xrefwindow id=d252e2732 href="http://www.ncbi.nlm.nih.gov/pubmed/9697870">PubMed Abstract </a> | <a target=xrefwindow id=d252e2735 href="http://dx.doi.org/10.1038/sj.leu.2401098">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e2745 class=n-a></a>Forster VJ, van Delft FW, Baird SF, <i> et al.</i>: Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. <i>Cancer Chemother Pharmacol.</i> 2016; <b>78</b>(5): 1093–6. <a target=xrefwindow id=d252e2756 href="http://www.ncbi.nlm.nih.gov/pubmed/27659182">PubMed Abstract </a> | <a target=xrefwindow id=d252e2759 href="http://dx.doi.org/10.1007/s00280-016-3153-0">Publisher Full Text </a> | <a target=xrefwindow id=d252e2763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5083755">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455040">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d252e2776 class=n-a></a>Bernini JC, Fort DW, Griener JC, <i> et al.</i>: Aminophylline for methotrexate-induced neurotoxicity. <i>Lancet.</i> 1995; <b>345</b>(8949): 544–7. <a target=xrefwindow id=d252e2787 href="http://www.ncbi.nlm.nih.gov/pubmed/7776773">PubMed Abstract </a> | <a target=xrefwindow id=d252e2790 href="http://dx.doi.org/10.1016/S0140-6736(95)90464-6">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d252e2799 class=n-a></a>Drachtman RA, Cole PD, Golden CB, <i> et al.</i>: Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. <i>Pediatr Hematol Oncol.</i> 2002; <b>19</b>(5): 319–27. <a target=xrefwindow id=d252e2810 href="http://www.ncbi.nlm.nih.gov/pubmed/12078863">PubMed Abstract </a> | <a target=xrefwindow id=d252e2813 href="http://dx.doi.org/10.1080/08880010290057336">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d252e2822 class=n-a></a>Haykin ME, Gorman M, van Hoff J, <i> et al.</i>: Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. <i>J Neurooncol.</i> 2006; <b>76</b>(2): 153–7. <a target=xrefwindow id=d252e2833 href="http://www.ncbi.nlm.nih.gov/pubmed/16411025">PubMed Abstract </a> | <a target=xrefwindow id=d252e2836 href="http://dx.doi.org/10.1007/s11060-005-9569-8">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d252e2845 class=n-a></a>Kim SJ, Im SA, Lee JW, <i> et al.</i>: Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia. <i>Pediatr Neurol.</i> 2012; <b>47</b>(6): 436–42. <a target=xrefwindow id=d252e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/23127265">PubMed Abstract </a> | <a target=xrefwindow id=d252e2859 href="http://dx.doi.org/10.1016/j.pediatrneurol.2012.07.011">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725851106"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e2868 class=n-a></a>Khan RB, Sadighi ZS, Zabrowski J, <i> et al.</i>: Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer Treatment. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(3): 523–6. <a target=xrefwindow id=d252e2879 href="http://www.ncbi.nlm.nih.gov/pubmed/26469881">PubMed Abstract </a> | <a target=xrefwindow id=d252e2882 href="http://dx.doi.org/10.1002/pbc.25790">Publisher Full Text </a> | <a target=xrefwindow id=d252e2886 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4724342">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725851106">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d252e2900 class=n-a></a>Ularntinon S, Tzuang D, Dahl G, <i> et al.</i>: Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. <i>Pediatrics.</i> 2010; <b>125</b>(5): e1241–5. <a target=xrefwindow id=d252e2911 href="http://www.ncbi.nlm.nih.gov/pubmed/20385646">PubMed Abstract </a> | <a target=xrefwindow id=d252e2914 href="http://dx.doi.org/10.1542/peds.2009-1815">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d252e2923 class=n-a></a>Wolf VL, Lupo PJ, Lotze TE: Pediatric acute transverse myelitis overview and differential diagnosis. <i>J Child Neurol.</i> 2012; <b>27</b>(11): 1426–36. <a target=xrefwindow id=d252e2931 href="http://www.ncbi.nlm.nih.gov/pubmed/22914370">PubMed Abstract </a> | <a target=xrefwindow id=d252e2934 href="http://dx.doi.org/10.1177/0883073812452916">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d252e2943 class=n-a></a>Yavuz H, Cakir M: Transverse myelopathy: an initial presentation of acute leukemia. <i>Pediatr Neurol.</i> 2001; <b>24</b>(5): 382–4. <a target=xrefwindow id=d252e2951 href="http://www.ncbi.nlm.nih.gov/pubmed/11516615">PubMed Abstract </a> | <a target=xrefwindow id=d252e2954 href="http://dx.doi.org/10.1016/S0887-8994(01)00258-2">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d252e2963 class=n-a></a>Schwenn MR, Blattner SR, Lynch E, <i> et al.</i>: HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 1991; <b>9</b>(1): 133–8. <a target=xrefwindow id=d252e2974 href="http://www.ncbi.nlm.nih.gov/pubmed/1985162">PubMed Abstract </a> | <a target=xrefwindow id=d252e2977 href="http://dx.doi.org/10.1200/JCO.1991.9.1.133">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725366485"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e2986 class=n-a></a>Diouf B, Crews KR, Lew G, <i> et al.</i>: Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. <i>JAMA.</i> 2015; <b>313</b>(8): 815–23. <a target=xrefwindow id=d252e2997 href="http://www.ncbi.nlm.nih.gov/pubmed/25710658">PubMed Abstract </a> | <a target=xrefwindow id=d252e3000 href="http://dx.doi.org/10.1001/jama.2015.0894">Publisher Full Text </a> | <a target=xrefwindow id=d252e3004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4377066">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725366485">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d252e3017 class=n-a></a>Addington J, Freimer M: Chemotherapy-induced peripheral neuropathy: an update on the current understanding [version 1; referees: 2 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-1466. <a target=xrefwindow id=d252e3025 href="http://www.ncbi.nlm.nih.gov/pubmed/27408692">PubMed Abstract </a> | <a target=xrefwindow id=d252e3028 href="http://dx.doi.org/10.12688/f1000research.8053.1">Publisher Full Text </a> | <a target=xrefwindow id=d252e3031 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4920214">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d252e3041 class=n-a></a>Nishikawa T, Kawakami K, Kumamoto T, <i> et al.</i>: Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. <i>J Pediatr Hematol Oncol.</i> 2008; <b>30</b>(7): 519–21. <a target=xrefwindow id=d252e3052 href="http://www.ncbi.nlm.nih.gov/pubmed/18797198">PubMed Abstract </a> | <a target=xrefwindow id=d252e3055 href="http://dx.doi.org/10.1097/MPH.0b013e31816624a4">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d252e3064 class=n-a></a>Graf WD, Chance PF, Lensch MW, <i> et al.</i>: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. <i>Cancer.</i> 1996; <b>77</b>(7): 1356–62. <a target=xrefwindow id=d252e3075 href="http://www.ncbi.nlm.nih.gov/pubmed/8608515">PubMed Abstract </a> | <a target="xrefwindow" id="d252e3078" href="http://dx.doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20&gt;3.0.CO;2-#">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d252e3087 class=n-a></a>Davidsen ML, Dalhoff K, Schmiegelow K: Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. <i>J Pediatr Hematol Oncol.</i> 2008; <b>30</b>(11): 831–49. <a target=xrefwindow id=d252e3095 href="http://www.ncbi.nlm.nih.gov/pubmed/18989161">PubMed Abstract </a> | <a target=xrefwindow id=d252e3098 href="http://dx.doi.org/10.1097/MPH.0b013e3181868570">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d252e3107 class=n-a></a>Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. <i>Clin Pharmacokinet.</i> 2000; <b>38</b>(2): 111–80. <a target=xrefwindow id=d252e3115 href="http://www.ncbi.nlm.nih.gov/pubmed/10709776">PubMed Abstract </a> | <a target=xrefwindow id=d252e3118 href="http://dx.doi.org/10.2165/00003088-200038020-00002">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d252e3127 class=n-a></a>Egbelakin A, Ferguson MJ, MacGill EA, <i> et al.</i>: Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2011; <b>56</b>(3): 361–7. <a target=xrefwindow id=d252e3138 href="http://www.ncbi.nlm.nih.gov/pubmed/21225912">PubMed Abstract </a> | <a target=xrefwindow id=d252e3141 href="http://dx.doi.org/10.1002/pbc.22845">Publisher Full Text </a> | <a target=xrefwindow id=d252e3145 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3020258">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d252e3154 class=n-a></a>Mitchell CD, Richards SM, Kinsey SE, <i> et al.</i>: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. <i>Br J Haematol.</i> 2005; <b>129</b>(6): 734–45. <a target=xrefwindow id=d252e3165 href="http://www.ncbi.nlm.nih.gov/pubmed/15952999">PubMed Abstract </a> | <a target=xrefwindow id=d252e3168 href="http://dx.doi.org/10.1111/j.1365-2141.2005.05509.x">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1149874"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3178 class=n-a></a>Halton J, Gaboury I, Grant R, <i> et al.</i>: Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. <i>J Bone Miner Res.</i> 2009; <b>24</b>(7): 1326–34. <a target=xrefwindow id=d252e3189 href="http://www.ncbi.nlm.nih.gov/pubmed/19210218">PubMed Abstract </a> | <a target=xrefwindow id=d252e3192 href="http://dx.doi.org/10.1359/jbmr.090202">Publisher Full Text </a> | <a target=xrefwindow id=d252e3196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3890351">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1149874">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976584"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3209 class=n-a></a>Vrooman LM, Stevenson KE, Supko JG, <i> et al.</i>: Postinduction dexamethasone and individualized dosing of <i>Escherichia Coli</i> L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>J Clin Oncol.</i> 2013; <b>31</b>(9): 1202–10. <a target=xrefwindow id=d252e3223 href="http://www.ncbi.nlm.nih.gov/pubmed/23358966">PubMed Abstract </a> | <a target=xrefwindow id=d252e3227 href="http://dx.doi.org/10.1200/JCO.2012.43.2070">Publisher Full Text </a> | <a target=xrefwindow id=d252e3230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3595424">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976584">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725809586"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3243 class=n-a></a>den Hoed MA, Pluijm SM, te Winkel ML, <i> et al.</i>: Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia. <i>Haematologica.</i> 2015; <b>100</b>(12): 1564–70. <a target=xrefwindow id=d252e3254 href="http://www.ncbi.nlm.nih.gov/pubmed/26405155">PubMed Abstract </a> | <a target=xrefwindow id=d252e3257 href="http://dx.doi.org/10.3324/haematol.2015.125583">Publisher Full Text </a> | <a target=xrefwindow id=d252e3261 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4666332">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725809586">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d252e3274 class=n-a></a>Wilson CL, Ness KK: Bone mineral density deficits and fractures in survivors of childhood cancer. <i>Curr Osteoporos Rep.</i> 2013; <b>11</b>(4): 329–37. <a target=xrefwindow id=d252e3282 href="http://www.ncbi.nlm.nih.gov/pubmed/24043370">PubMed Abstract </a> | <a target=xrefwindow id=d252e3285 href="http://dx.doi.org/10.1007/s11914-013-0165-0">Publisher Full Text </a> | <a target=xrefwindow id=d252e3288 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4260527">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d252e3297 class=n-a></a>Toft N, Birgens H, Abrahamsson J, <i> et al.</i>: Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Eur J Haematol.</i> 2016; <b>96</b>(2): 160–9. <a target=xrefwindow id=d252e3308 href="http://www.ncbi.nlm.nih.gov/pubmed/25867866">PubMed Abstract </a> | <a target=xrefwindow id=d252e3311 href="http://dx.doi.org/10.1111/ejh.12562">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d252e3320 class=n-a></a>Kuhlen M, Moldovan A, Krull K, <i> et al.</i>: Osteonecrosis in paediatric patients with acute lymphoblastic leukaemia treated on Co-ALL-07-03 trial: a single centre analysis. <i>Klin Padiatr.</i> 2014; <b>226</b>(3): 154–60. <a target=xrefwindow id=d252e3331 href="http://www.ncbi.nlm.nih.gov/pubmed/24710762">PubMed Abstract </a> | <a target=xrefwindow id=d252e3334 href="http://dx.doi.org/10.1055/s-0033-1358723">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10573960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3344 class=n-a></a>Kawedia JD, Kaste SC, Pei D, <i> et al.</i>: Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood.</i> 2011; <b>117</b>(8): 2340–7; quiz 2556. <a target=xrefwindow id=d252e3355 href="http://www.ncbi.nlm.nih.gov/pubmed/21148812">PubMed Abstract </a> | <a target=xrefwindow id=d252e3358 href="http://dx.doi.org/10.1182/blood-2010-10-311969">Publisher Full Text </a> | <a target=xrefwindow id=d252e3362 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3062406">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10573960">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954862"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3375 class=n-a></a>Mattano LA Jr, Devidas M, Nachman JB, <i> et al.</i>: Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. <i>Lancet Oncol.</i> 2012; <b>13</b>(9): 906–15. <a target=xrefwindow id=d252e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/22901620">PubMed Abstract </a> | <a target=xrefwindow id=d252e3389 href="http://dx.doi.org/10.1016/S1470-2045(12)70274-7">Publisher Full Text </a> | <a target=xrefwindow id=d252e3393 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3448283">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954862">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d252e3406 class=n-a></a>Kunstreich M, Kummer S, Laws HJ, <i> et al.</i>: Osteonecrosis in children with acute lymphoblastic leukemia. <i>Haematologica.</i> 2016; <b>101</b>(11): 1295–305. <a target=xrefwindow id=d252e3417 href="http://www.ncbi.nlm.nih.gov/pubmed/27742768">PubMed Abstract </a> | <a target=xrefwindow id=d252e3420 href="http://dx.doi.org/10.3324/haematol.2016.147595">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d252e3429 class=n-a></a>te Winkel ML, Pieters R, Hop WC, <i> et al.</i>: Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2011; <b>29</b>(31): 4143–50. <a target=xrefwindow id=d252e3440 href="http://www.ncbi.nlm.nih.gov/pubmed/21947829">PubMed Abstract </a> | <a target=xrefwindow id=d252e3443 href="http://dx.doi.org/10.1200/JCO.2011.37.3217">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d252e3452 class=n-a></a>Girard P, Auquier P, Barlogis V, <i> et al.</i>: Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood. <i>Haematologica.</i> 2013; <b>98</b>(7): 1089–97. <a target=xrefwindow id=d252e3463 href="http://www.ncbi.nlm.nih.gov/pubmed/23645686">PubMed Abstract </a> | <a target=xrefwindow id=d252e3466 href="http://dx.doi.org/10.3324/haematol.2012.081265">Publisher Full Text </a> | <a target=xrefwindow id=d252e3470 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3696613">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d252e3479 class=n-a></a>Bhojwani D, Darbandi R, Pei D, <i> et al.</i>: Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. <i>Eur J Cancer.</i> 2014; <b>50</b>(15): 2685–94. <a target=xrefwindow id=d252e3490 href="http://www.ncbi.nlm.nih.gov/pubmed/25087182">PubMed Abstract </a> | <a target=xrefwindow id=d252e3493 href="http://dx.doi.org/10.1016/j.ejca.2014.06.023">Publisher Full Text </a> | <a target=xrefwindow id=d252e3497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4180109">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725715241"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3507 class=n-a></a>Karol SE, Yang W, van Driest SL, <i> et al.</i>: Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood.</i> 2015; <b>126</b>(15): 1770–6. <a target=xrefwindow id=d252e3518 href="http://www.ncbi.nlm.nih.gov/pubmed/26265699">PubMed Abstract </a> | <a target=xrefwindow id=d252e3521 href="http://dx.doi.org/10.1182/blood-2015-05-643601">Publisher Full Text </a> | <a target=xrefwindow id=d252e3525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4600016">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725715241">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725951429"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3538 class=n-a></a>Karol SE, Mattano LA Jr, Yang W, <i> et al.</i>: Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood.</i> 2016; <b>127</b>(5): 558–64. <a target=xrefwindow id=d252e3549 href="http://www.ncbi.nlm.nih.gov/pubmed/26590194">PubMed Abstract </a> | <a target=xrefwindow id=d252e3552 href="http://dx.doi.org/10.1182/blood-2015-10-673848">Publisher Full Text </a> | <a target=xrefwindow id=d252e3556 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4742546">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725951429">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727105440"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3569 class=n-a></a>Finkelstein Y, Blonquist TM, Vijayanathan V, <i> et al.</i>: A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2016. <a target=xrefwindow id=d252e3577 href="http://www.ncbi.nlm.nih.gov/pubmed/27957785">PubMed Abstract </a> | <a target=xrefwindow id=d252e3580 href="http://dx.doi.org/10.1002/pbc.26393">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727105440">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/724887267"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3593 class=n-a></a>Niinimäki T, Harila-Saari A, Niinimäki R: The diagnosis and classification of osteonecrosis in patients with childhood leukemia. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(2): 198–203. <a target=xrefwindow id=d252e3601 href="http://www.ncbi.nlm.nih.gov/pubmed/25359608">PubMed Abstract </a> | <a target=xrefwindow id=d252e3604 href="http://dx.doi.org/10.1002/pbc.25295">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/724887267">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455047"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3617 class=n-a></a>Niinimäki T, Niinimäki J, Halonen J, <i> et al.</i>: The classification of osteonecrosis in patients with cancer: validation of a new radiological classification system. <i>Clin Radiol.</i> 2015; <b>70</b>(12): 1439–44. <a target=xrefwindow id=d252e3628 href="http://www.ncbi.nlm.nih.gov/pubmed/26453406">PubMed Abstract </a> | <a target=xrefwindow id=d252e3631 href="http://dx.doi.org/10.1016/j.crad.2015.08.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455047">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d252e3644 class=n-a></a>Qureshi A, Mitchell C, Richards S, <i> et al.</i>: Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. <i>Br J Haematol.</i> 2010; <b>149</b>(3): 410–3. <a target=xrefwindow id=d252e3655 href="http://www.ncbi.nlm.nih.gov/pubmed/20201945">PubMed Abstract </a> | <a target=xrefwindow id=d252e3658 href="http://dx.doi.org/10.1111/j.1365-2141.2010.08132.x">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d252e3668 class=n-a></a>Grace RF, Dahlberg SE, Neuberg D, <i> et al.</i>: The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>Br J Haematol.</i> 2011; <b>152</b>(4): 452–9. <a target=xrefwindow id=d252e3679 href="http://www.ncbi.nlm.nih.gov/pubmed/21210774">PubMed Abstract </a> | <a target=xrefwindow id=d252e3682 href="http://dx.doi.org/10.1111/j.1365-2141.2010.08524.x">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d252e3691 class=n-a></a>Santoro N, Colombini A, Silvestri D, <i> et al.</i>: Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. <i>J Pediatr Hematol Oncol.</i> 2013; <b>35</b>(5): 348–55. <a target=xrefwindow id=d252e3702 href="http://www.ncbi.nlm.nih.gov/pubmed/23619106">PubMed Abstract </a> | <a target=xrefwindow id=d252e3705 href="http://dx.doi.org/10.1097/MPH.0b013e31828dc614">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d252e3714 class=n-a></a>Caruso V, Iacoviello L, Di Castelnuovo A, <i> et al.</i>: Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. <i>Blood.</i> 2006; <b>108</b>(7): 2216–22. <a target=xrefwindow id=d252e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/16804111">PubMed Abstract </a> | <a target=xrefwindow id=d252e3728 href="http://dx.doi.org/10.1182/blood-2006-04-015511">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d252e3737 class=n-a></a>Tuckuviene R, Ranta S, Albertsen BK, <i> et al.</i>: Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. <i>J Thromb Haemost.</i> 2016; <b>14</b>(3): 485–94. <a target=xrefwindow id=d252e3748 href="http://www.ncbi.nlm.nih.gov/pubmed/26707629">PubMed Abstract </a> | <a target=xrefwindow id=d252e3751 href="http://dx.doi.org/10.1111/jth.13236">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d252e3760 class=n-a></a>Farinasso L, Bertorello N, Garbarini L, <i> et al.</i>: Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. <i>Leukemia.</i> 2007; <b>21</b>(3): 552–6. <a target=xrefwindow id=d252e3771 href="http://www.ncbi.nlm.nih.gov/pubmed/17268522">PubMed Abstract </a> | <a target=xrefwindow id=d252e3774 href="http://dx.doi.org/10.1038/sj.leu.2404560">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d252e3783 class=n-a></a>Payne JH, Vora AJ: Thrombosis and acute lymphoblastic leukaemia. <i>Br J Haematol.</i> 2007; <b>138</b>(4): 430–45. <a target=xrefwindow id=d252e3791 href="http://www.ncbi.nlm.nih.gov/pubmed/17608766">PubMed Abstract </a> | <a target=xrefwindow id=d252e3794 href="http://dx.doi.org/10.1111/j.1365-2141.2007.06677.x">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723875904"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3804 class=n-a></a>De Stefano V, Za T, Ciminello A, <i> et al.</i>: Haemostatic alterations induced by treatment with asparaginases and clinical consequences. <i>Thromb Haemost.</i> 2015; <b>113</b>(2): 247–61. <a target=xrefwindow id=d252e3815 href="http://www.ncbi.nlm.nih.gov/pubmed/25338526">PubMed Abstract </a> | <a target=xrefwindow id=d252e3818 href="http://dx.doi.org/10.1160/TH14-04-0372">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723875904">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d252e3831 class=n-a></a>Ranta S, Tuckuviene R, Makipernaa A, <i> et al.</i>: Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. <i>Br J Haematol.</i> 2015; <b>168</b>(4): 547–52. <a target=xrefwindow id=d252e3842 href="http://www.ncbi.nlm.nih.gov/pubmed/25288392">PubMed Abstract </a> | <a target=xrefwindow id=d252e3845 href="http://dx.doi.org/10.1111/bjh.13162">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455048"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e3854 class=n-a></a>Musgrave KM, van Delft FW, Avery PJ, <i> et al.</i>: Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom. <i>Br J Haematol.</i> 2016. <a target=xrefwindow id=d252e3862 href="http://www.ncbi.nlm.nih.gov/pubmed/27392277">PubMed Abstract </a> | <a target=xrefwindow id=d252e3865 href="http://dx.doi.org/10.1111/bjh.14231">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455048">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d252e3878 class=n-a></a>DeLeve LD, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). <i>Semin Liver Dis.</i> 2002; <b>22</b>(1): 27–42. <a target=xrefwindow id=d252e3886 href="http://www.ncbi.nlm.nih.gov/pubmed/11928077">PubMed Abstract </a> | <a target=xrefwindow id=d252e3889 href="http://dx.doi.org/10.1055/s-2002-23204">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d252e3898 class=n-a></a>Escherich G, Richards S, Stork LC, <i> et al.</i>: Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. <i>Leukemia.</i> 2011; <b>25</b>(6): 953–9. <a target=xrefwindow id=d252e3909 href="http://www.ncbi.nlm.nih.gov/pubmed/21372841">PubMed Abstract </a> | <a target=xrefwindow id=d252e3912 href="http://dx.doi.org/10.1038/leu.2011.37">Publisher Full Text </a> | <a target=xrefwindow id=d252e3916 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3112460">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d252e3925 class=n-a></a>Lennard L, Richards S, Cartwright CS, <i> et al.</i>: The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. <i>Clin Pharmacol Ther.</i> 2006; <b>80</b>(4): 375–83. <a target=xrefwindow id=d252e3936 href="http://www.ncbi.nlm.nih.gov/pubmed/17015055">PubMed Abstract </a> | <a target=xrefwindow id=d252e3939 href="http://dx.doi.org/10.1016/j.clpt.2006.07.002">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d252e3949 class=n-a></a>Helmy A: Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. <i>Aliment Pharmacol Ther.</i> 2006; <b>23</b>(1): 11–25. <a target=xrefwindow id=d252e3957 href="http://www.ncbi.nlm.nih.gov/pubmed/16393276">PubMed Abstract </a> | <a target=xrefwindow id=d252e3960 href="http://dx.doi.org/10.1111/j.1365-2036.2006.02742.x">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d252e3969 class=n-a></a>DeLeve LD: Vascular Liver Disease and the Liver Sinusoidal Endothelial Cell. In: <i>Vascular liver disease</i>. deLeve LD Garcia-Tsao G; editors. New York: Springer New York; 2011; 25–40. <a target=xrefwindow id=d252e3974 href="http://dx.doi.org/10.1007/978-1-4419-8327-5_2">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d252e3983 class=n-a></a>Toksvang LN, De Pietri S, Nielsen SN, <i> et al.</i>: Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukaemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. <i>Pediatr Blood Cancer.</i> 2017, in press. </span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d252e3998 class=n-a></a>Schmiegelow M, Hertz H, Schmiegelow K, <i> et al.</i>: Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children. <i>J Pediatr Hematol Oncol.</i> 1999; <b>21</b>(4): 268–73. <a target=xrefwindow id=d252e4009 href="http://www.ncbi.nlm.nih.gov/pubmed/10445888">PubMed Abstract </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d252e4018 class=n-a></a>Howard SC, Pui CH: Endocrine complications in pediatric patients with acute lymphoblastic leukemia. <i>Blood Rev.</i> 2002; <b>16</b>(4): 225–43. <a target=xrefwindow id=d252e4026 href="http://www.ncbi.nlm.nih.gov/pubmed/12350366">PubMed Abstract </a> | <a target=xrefwindow id=d252e4029 href="http://dx.doi.org/10.1016/S0268-960X(02)00042-5">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d252e4038 class=n-a></a>Vandecruys E, Dhooge C, Craen M, <i> et al.</i>: Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation. <i>J Pediatr.</i> 2013; <b>163</b>(1): 268–73. <a target=xrefwindow id=d252e4049 href="http://www.ncbi.nlm.nih.gov/pubmed/23351599">PubMed Abstract </a> | <a target=xrefwindow id=d252e4052 href="http://dx.doi.org/10.1016/j.jpeds.2012.12.037">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d252e4062 class=n-a></a>Mohn A, Di Marzio A, Capanna R, <i> et al.</i>: Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. <i>Lancet.</i> 2004; <b>363</b>(9403): 127–8. <a target=xrefwindow id=d252e4073 href="http://www.ncbi.nlm.nih.gov/pubmed/14726167">PubMed Abstract </a> | <a target=xrefwindow id=d252e4076 href="http://dx.doi.org/10.1016/S0140-6736(03)15264-6">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d252e4085 class=n-a></a>White J, Flohr JA, Winter SS, <i> et al.</i>: Potential benefits of physical activity for children with acute lymphoblastic leukaemia. <i>Pediatr Rehabil.</i> 2005; <b>8</b>(1): 53–8. <a target=xrefwindow id=d252e4096 href="http://www.ncbi.nlm.nih.gov/pubmed/15799136">PubMed Abstract </a> | <a target=xrefwindow id=d252e4099 href="http://dx.doi.org/10.1080/13638490410001727428">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d252e4108 class=n-a></a>Esbenshade AJ, Simmons JH, Friedman DL: BMI alterations during treatment of childhood ALL-response. <i>Pediatr Blood Cancer.</i> 2012; <b>58</b>(6): 1000. <a target=xrefwindow id=d252e4116 href="http://www.ncbi.nlm.nih.gov/pubmed/22038953">PubMed Abstract </a> | <a target=xrefwindow id=d252e4119 href="http://dx.doi.org/10.1002/pbc.23379">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d252e4128 class=n-a></a>Chow EJ, Pihoker C, Friedman DL, <i> et al.</i>: Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(4): 621–6. <a target=xrefwindow id=d252e4139 href="http://www.ncbi.nlm.nih.gov/pubmed/23042765">PubMed Abstract </a> | <a target=xrefwindow id=d252e4142 href="http://dx.doi.org/10.1002/pbc.24364">Publisher Full Text </a> | <a target=xrefwindow id=d252e4146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3568436">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d252e4155 class=n-a></a>Pui CH, Burghen GA, Bowman WP, <i> et al.</i>: Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. <i>J Pediatr.</i> 1981; <b>99</b>(1): 46–50. <a target=xrefwindow id=d252e4166 href="http://www.ncbi.nlm.nih.gov/pubmed/6454771">PubMed Abstract </a> | <a target=xrefwindow id=d252e4169 href="http://dx.doi.org/10.1016/S0022-3476(81)80955-9">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d252e4178 class=n-a></a>Lowas S, Malempati S, Marks D: Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2009; <b>53</b>(1): 58–63. <a target=xrefwindow id=d252e4186 href="http://www.ncbi.nlm.nih.gov/pubmed/19340854">PubMed Abstract </a> | <a target=xrefwindow id=d252e4189 href="http://dx.doi.org/10.1002/pbc.21993">Publisher Full Text </a> | <a target=xrefwindow id=d252e4192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3804011">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d252e4202 class=n-a></a>Baillargeon J, Langevin AM, Mullins J, <i> et al.</i>: Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2005; <b>45</b>(7): 960–3. <a target=xrefwindow id=d252e4213 href="http://www.ncbi.nlm.nih.gov/pubmed/15700246">PubMed Abstract </a> | <a target=xrefwindow id=d252e4216 href="http://dx.doi.org/10.1002/pbc.20320">Publisher Full Text </a> | <a target=xrefwindow id=d252e4220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3102306">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d252e4229 class=n-a></a>Koltin D, Sung L, Naqvi A, <i> et al.</i>: Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. <i>Support Care Cancer.</i> 2012; <b>20</b>(9): 2009–15. <a target=xrefwindow id=d252e4240 href="http://www.ncbi.nlm.nih.gov/pubmed/22065148">PubMed Abstract </a> | <a target=xrefwindow id=d252e4243 href="http://dx.doi.org/10.1007/s00520-011-1307-5">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455049"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4252 class=n-a></a>Yeshayahu Y, Koltin D, Hamilton J, <i> et al.</i>: Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk? <i>Pediatr Diabetes.</i> 2015; <b>16</b>(2): 104–8. <a target=xrefwindow id=d252e4263 href="http://www.ncbi.nlm.nih.gov/pubmed/24673941">PubMed Abstract </a> | <a target=xrefwindow id=d252e4266 href="http://dx.doi.org/10.1111/pedi.12138">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455049">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d252e4279 class=n-a></a>Sonabend RY, McKay SV, Okcu MF, <i> et al.</i>: Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. <i>J Pediatr.</i> 2009; <b>155</b>(1): 73–8. <a target=xrefwindow id=d252e4290 href="http://www.ncbi.nlm.nih.gov/pubmed/19394046">PubMed Abstract </a> | <a target=xrefwindow id=d252e4293 href="http://dx.doi.org/10.1016/j.jpeds.2009.01.072">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d252e4302 class=n-a></a>Butturini AM, Dorey FJ, Lange BJ, <i> et al.</i>: Obesity and outcome in pediatric acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2007; <b>25</b>(15): 2063–9. <a target=xrefwindow id=d252e4313 href="http://www.ncbi.nlm.nih.gov/pubmed/17513811">PubMed Abstract </a> | <a target=xrefwindow id=d252e4316 href="http://dx.doi.org/10.1200/JCO.2006.07.7792">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d252e4325 class=n-a></a>Halonen P, Salo MK, Schmiegelow K, <i> et al.</i>: Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. <i>Acta Paediatr.</i> 2003; <b>92</b>(1): 37–42. <a target=xrefwindow id=d252e4336 href="http://www.ncbi.nlm.nih.gov/pubmed/12650297">PubMed Abstract </a> | <a target=xrefwindow id=d252e4339 href="http://dx.doi.org/10.1111/j.1651-2227.2003.tb00466.x">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d252e4349 class=n-a></a>Bay A, Oner AF, Cesur Y, <i> et al.</i>: Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL. <i>Pediatr Blood Cancer.</i> 2006; <b>47</b>(3): 330–1. <a target=xrefwindow id=d252e4360 href="http://www.ncbi.nlm.nih.gov/pubmed/16047348">PubMed Abstract </a> | <a target=xrefwindow id=d252e4363 href="http://dx.doi.org/10.1002/pbc.20582">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d252e4372 class=n-a></a>Trelinska J, Fendler W, Szadkowska A, <i> et al.</i>: Hypoglycemia and glycemic variability among children with acute lymphoblastic leukemia during maintenance therapy. <i>Leuk Lymphoma.</i> 2011; <b>52</b>(9): 1704–10. <a target=xrefwindow id=d252e4383 href="http://www.ncbi.nlm.nih.gov/pubmed/21585281">PubMed Abstract </a> | <a target=xrefwindow id=d252e4386 href="http://dx.doi.org/10.3109/10428194.2011.580024">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725726365"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4395 class=n-a></a>Gordijn MS, Rensen N, Gemke RJ, <i> et al.</i>: Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. <i>Cochrane Database Syst Rev.</i> 2015; (8): CD008727. <a target=xrefwindow id=d252e4403 href="http://www.ncbi.nlm.nih.gov/pubmed/26282194">PubMed Abstract </a> | <a target=xrefwindow id=d252e4406 href="http://dx.doi.org/10.1002/14651858.CD008727.pub3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725726365">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455050"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4419 class=n-a></a>Salem MA, Tantawy AA, El Sedfy HH, <i> et al.</i>: A prospective study of the hypothalamic-pituitary-adrenal axis in children with acute lymphoblastic leukemia receiving chemotherapy. <i>Hematology.</i> 2015; <b>20</b>(6): 320–7. <a target=xrefwindow id=d252e4430 href="http://www.ncbi.nlm.nih.gov/pubmed/25321891">PubMed Abstract </a> | <a target=xrefwindow id=d252e4433 href="http://dx.doi.org/10.1179/1607845414Y.0000000208">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455050">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d252e4446 class=n-a></a>de Ruiter RD, Gordijn MS, Gemke RJ, <i> et al.</i>: Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and <i>Bcl</i>I. <i>Haematologica.</i> 2014; <b>99</b>(8): e136–7. <a target=xrefwindow id=d252e4460 href="http://www.ncbi.nlm.nih.gov/pubmed/24816241">PubMed Abstract </a> | <a target=xrefwindow id=d252e4464 href="http://dx.doi.org/10.3324/haematol.2014.105056">Publisher Full Text </a> | <a target=xrefwindow id=d252e4467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4116845">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d252e4476 class=n-a></a>Skärby T, Jönsson P, Hjorth L, <i> et al.</i>: High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). <i>Cancer Chemother Pharmacol.</i> 2003; <b>51</b>(4): 311–20. <a target=xrefwindow id=d252e4487 href="http://www.ncbi.nlm.nih.gov/pubmed/12721759">PubMed Abstract </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14225959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4497 class=n-a></a>Christensen AM, Pauley JL, Molinelli AR, <i> et al.</i>: Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. <i>Cancer.</i> 2012; <b>118</b>(17): 4321–30. <a target=xrefwindow id=d252e4508 href="http://www.ncbi.nlm.nih.gov/pubmed/22252903">PubMed Abstract </a> | <a target=xrefwindow id=d252e4511 href="http://dx.doi.org/10.1002/cncr.27378">Publisher Full Text </a> | <a target=xrefwindow id=d252e4515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3713608">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14225959">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d252e4528 class=n-a></a>Widemann BC, Schwartz S, Jayaprakash N, <i> et al.</i>: Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. <i>Pharmacotherapy.</i> 2014; <b>34</b>(5): 427–39. <a target=xrefwindow id=d252e4539 href="http://www.ncbi.nlm.nih.gov/pubmed/24132809">PubMed Abstract </a> | <a target=xrefwindow id=d252e4542 href="http://dx.doi.org/10.1002/phar.1360">Publisher Full Text </a> | <a target=xrefwindow id=d252e4546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3990659">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d252e4555 class=n-a></a>Svahn T, Mellgren K, Harila-Saari A, <i> et al.</i>: Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2016. <a target=xrefwindow id=d252e4563 href="http://www.ncbi.nlm.nih.gov/pubmed/27966809">PubMed Abstract </a> | <a target=xrefwindow id=d252e4566 href="http://dx.doi.org/10.1002/pbc.26395">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d252e4575 class=n-a></a>Sand TE, Jacobsen S: Effect of urine pH and flow on renal clearance of methotrexate. <i>Eur J Clin Pharmacol.</i> 1981; <b>19</b>(6): 453–6. <a target=xrefwindow id=d252e4583 href="http://www.ncbi.nlm.nih.gov/pubmed/7250179">PubMed Abstract </a> | <a target=xrefwindow id=d252e4586 href="http://dx.doi.org/10.1007/BF00548590">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455052"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4595 class=n-a></a>Garneau AP, Riopel J, Isenring P: Acute Methotrexate-Induced Crystal Nephropathy. <i>N Engl J Med.</i> 2015; <b>373</b>(7): 2691–3. <a target=xrefwindow id=d252e4603 href="http://www.ncbi.nlm.nih.gov/pubmed/26716929">PubMed Abstract </a> | <a target=xrefwindow id=d252e4606 href="http://dx.doi.org/10.1056/NEJMc1507547">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455052">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d252e4619 class=n-a></a>Skärby TV, Anderson H, Heldrup J, <i> et al.</i>: High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. <i>Leukemia.</i> 2006; <b>20</b>(11): 1955–62. <a target=xrefwindow id=d252e4630 href="http://www.ncbi.nlm.nih.gov/pubmed/16990760">PubMed Abstract </a> | <a target=xrefwindow id=d252e4633 href="http://dx.doi.org/10.1038/sj.leu.2404404">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d252e4643 class=n-a></a>Cohen IJ: Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). <i>Med Hypotheses.</i> 2013; <b>81</b>(5): 942–7. <a target=xrefwindow id=d252e4651 href="http://www.ncbi.nlm.nih.gov/pubmed/24035689">PubMed Abstract </a> | <a target=xrefwindow id=d252e4654 href="http://dx.doi.org/10.1016/j.mehy.2013.08.027">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d252e4663 class=n-a></a>Mikkelsen TS, Mamoudou AD, Tuckuviene R, <i> et al.</i>: Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(2): 297–301. <a target=xrefwindow id=d252e4674 href="http://www.ncbi.nlm.nih.gov/pubmed/24039194">PubMed Abstract </a> | <a target=xrefwindow id=d252e4677 href="http://dx.doi.org/10.1002/pbc.24623">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d252e4686 class=n-a></a>Treon SP, Chabner BA: Concepts in use of high-dose methotrexate therapy. <i>Clin Chem.</i> 1996; <b>42</b>(8 Pt 2): 1322–9. <a target=xrefwindow id=d252e4694 href="http://www.ncbi.nlm.nih.gov/pubmed/8697606">PubMed Abstract </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d252e4703 class=n-a></a>Widemann BC, Adamson PC: Understanding and managing methotrexate nephrotoxicity. <i>Oncologist.</i> 2006; <b>11</b>(6): 694–703. <a target=xrefwindow id=d252e4711 href="http://www.ncbi.nlm.nih.gov/pubmed/16794248">PubMed Abstract </a> | <a target=xrefwindow id=d252e4714 href="http://dx.doi.org/10.1634/theoncologist.11-6-694">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d252e4723 class=n-a></a>Suzuki K, Doki K, Homma M, <i> et al.</i>: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. <i>Br J Clin Pharmacol.</i> 2009; <b>67</b>(1): 44–9. <a target=xrefwindow id=d252e4734 href="http://www.ncbi.nlm.nih.gov/pubmed/19076159">PubMed Abstract </a> | <a target=xrefwindow id=d252e4737 href="http://dx.doi.org/10.1111/j.1365-2125.2008.03303.x">Publisher Full Text </a> | <a target=xrefwindow id=d252e4741 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2668083">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d252e4750 class=n-a></a>Joerger M, Huitema AD, van den Bongard HJ, <i> et al.</i>: Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. <i>Br J Clin Pharmacol.</i> 2006; <b>62</b>(1): 71–80. <a target=xrefwindow id=d252e4761 href="http://www.ncbi.nlm.nih.gov/pubmed/16842380">PubMed Abstract </a> | <a target=xrefwindow id=d252e4764 href="http://dx.doi.org/10.1111/j.1365-2125.2005.02513.x">Publisher Full Text </a> | <a target=xrefwindow id=d252e4768 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1885068">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d252e4778 class=n-a></a>Bauters TG, Verlooy J, Robays H, <i> et al.</i>: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. <i>Pharm World Sci.</i> 2008; <b>30</b>(4): 316–8. <a target=xrefwindow id=d252e4789 href="http://www.ncbi.nlm.nih.gov/pubmed/18386155">PubMed Abstract </a> | <a target=xrefwindow id=d252e4792 href="http://dx.doi.org/10.1007/s11096-008-9204-9">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d252e4801 class=n-a></a>Ronchera CL, Hernández T, Peris JE, <i> et al.</i>: Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. <i>Ther Drug Monit.</i> 1993; <b>15</b>(5): 375–9. <a target=xrefwindow id=d252e4812 href="http://www.ncbi.nlm.nih.gov/pubmed/8249043">PubMed Abstract </a> | <a target=xrefwindow id=d252e4815 href="http://dx.doi.org/10.1097/00007691-199310000-00004">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d252e4824 class=n-a></a>Thyss A, Milano G, Kubar J, <i> et al.</i>: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. <i>Lancet.</i> 1986; <b>1</b>(8475): 256–8. <a target=xrefwindow id=d252e4835 href="http://www.ncbi.nlm.nih.gov/pubmed/2868265">PubMed Abstract </a> | <a target=xrefwindow id=d252e4838 href="http://dx.doi.org/10.1016/S0140-6736(86)90786-5">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d252e4847 class=n-a></a>de Miguel D, García-Suárez J, Martin Y, <i> et al.</i>: Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. <i>Nephrol Dial Transplant.</i> 2008; <b>23</b>(12): 3762–6. <a target=xrefwindow id=d252e4858 href="http://www.ncbi.nlm.nih.gov/pubmed/18779628">PubMed Abstract </a> | <a target=xrefwindow id=d252e4861 href="http://dx.doi.org/10.1093/ndt/gfn503">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455053"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4870 class=n-a></a>Loue C, Garnier N, Bertrand Y, <i> et al.</i>: High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib. <i>J Clin Pharm Ther.</i> 2015. <a target=xrefwindow id=d252e4878 href="http://www.ncbi.nlm.nih.gov/pubmed/26073789">PubMed Abstract </a> | <a target=xrefwindow id=d252e4881 href="http://dx.doi.org/10.1111/jcpt.12298">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455053">F1000 Recommendation</a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d252e4894 class=n-a></a>Lin SP, Tsai SY, Hou YC, <i> et al.</i>: Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats. <i>J Agric Food Chem.</i> 2009; <b>57</b>(5): 1854–9. <a target=xrefwindow id=d252e4905 href="http://www.ncbi.nlm.nih.gov/pubmed/19209930">PubMed Abstract </a> | <a target=xrefwindow id=d252e4908 href="http://dx.doi.org/10.1021/jf8029918">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d252e4918 class=n-a></a>Santucci R, Levêque D, Herbrecht R: Cola beverage and delayed elimination of methotrexate. <i>Br J Clin Pharmacol.</i> 2010; <b>70</b>(5): 762–4. <a target=xrefwindow id=d252e4926 href="http://www.ncbi.nlm.nih.gov/pubmed/21545633">PubMed Abstract </a> | <a target=xrefwindow id=d252e4929 href="http://dx.doi.org/10.1111/j.1365-2125.2010.03744.x">Publisher Full Text </a> | <a target=xrefwindow id=d252e4932 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2997317">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e4941 class=n-a></a>Watts CS, Sciasci JN, Pauley JL, <i> et al.</i>: Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. <i>J Pediatr Hematol Oncol.</i> 2016; <b>38</b>(6): 449–52. <a target=xrefwindow id=d252e4952 href="http://www.ncbi.nlm.nih.gov/pubmed/27322715">PubMed Abstract </a> | <a target=xrefwindow id=d252e4955 href="http://dx.doi.org/10.1097/MPH.0000000000000606">Publisher Full Text </a> | <a target=xrefwindow id=d252e4959 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4955728">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455054">F1000 Recommendation</a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d252e4972 class=n-a></a>Treviño LR, Shimasaki N, Yang W, <i> et al.</i>: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. <i>J Clin Oncol.</i> 2009; <b>27</b>(35): 5972–8. <a target=xrefwindow id=d252e4983 href="http://www.ncbi.nlm.nih.gov/pubmed/19901119">PubMed Abstract </a> | <a target=xrefwindow id=d252e4986 href="http://dx.doi.org/10.1200/JCO.2008.20.4156">Publisher Full Text </a> | <a target=xrefwindow id=d252e4990 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2793040">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d252e4999 class=n-a></a>Gregers J, Christensen IJ, Dalhoff K, <i> et al.</i>: The association of reduced folate carrier 80G&gt;A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. <i>Blood.</i> 2010; <b>115</b>(23): 4671–7. <a target=xrefwindow id=d252e5010 href="http://www.ncbi.nlm.nih.gov/pubmed/20335220">PubMed Abstract </a> | <a target=xrefwindow id=d252e5013 href="http://dx.doi.org/10.1182/blood-2010-01-256958">Publisher Full Text </a> | <a target=xrefwindow id=d252e5017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2890175">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d252e5026 class=n-a></a>Mikkelsen TS, Thorn CF, Yang JJ, <i> et al.</i>: PharmGKB summary: methotrexate pathway. <i>Pharmacogenet Genomics.</i> 2011; <b>21</b>(10): 679–86. <a target=xrefwindow id=d252e5037 href="http://www.ncbi.nlm.nih.gov/pubmed/21317831">PubMed Abstract </a> | <a target=xrefwindow id=d252e5040 href="http://dx.doi.org/10.1097/FPC.0b013e328343dd93">Publisher Full Text </a> | <a target=xrefwindow id=d252e5044 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3139712">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717969444"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5053 class=n-a></a>Ramsey LB, Panetta JC, Smith C, <i> et al.</i>: Genome-wide study of methotrexate clearance replicates <i>SLCO1B1</i>. <i>Blood.</i> 2013; <b>121</b>(6): 898–904. <a target=xrefwindow id=d252e5067 href="http://www.ncbi.nlm.nih.gov/pubmed/23233662">PubMed Abstract </a> | <a target=xrefwindow id=d252e5071 href="http://dx.doi.org/10.1182/blood-2012-08-452839">Publisher Full Text </a> | <a target=xrefwindow id=d252e5074 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3567337">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717969444">F1000 Recommendation</a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d252e5088 class=n-a></a>Silverman LB, Gelber RD, Dalton VK, <i> et al.</i>: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. <i>Blood.</i> 2001; <b>97</b>(5): 1211–8. <a target=xrefwindow id=d252e5099 href="http://www.ncbi.nlm.nih.gov/pubmed/11222362">PubMed Abstract </a> | <a target=xrefwindow id=d252e5102 href="http://dx.doi.org/10.1182/blood.V97.5.1211">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d252e5111 class=n-a></a>Sirvent N, Suciu S, Rialland X, <i> et al.</i>: Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. <i>Eur J Cancer.</i> 2011; <b>47</b>(2): 239–47. <a target=xrefwindow id=d252e5122 href="http://www.ncbi.nlm.nih.gov/pubmed/21095115">PubMed Abstract </a> | <a target=xrefwindow id=d252e5125 href="http://dx.doi.org/10.1016/j.ejca.2010.10.019">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d252e5134 class=n-a></a>Asselin BL, Whitin JC, Coppola DJ, <i> et al.</i>: Comparative pharmacokinetic studies of three asparaginase preparations. <i>J Clin Oncol.</i> 1993; <b>11</b>(9): 1780–6. <a target=xrefwindow id=d252e5145 href="http://www.ncbi.nlm.nih.gov/pubmed/8355045">PubMed Abstract </a> | <a target=xrefwindow id=d252e5148 href="http://dx.doi.org/10.1200/JCO.1993.11.9.1780">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d252e5157 class=n-a></a>Albertsen BK, Schroder H, Ingerslev J, <i> et al.</i>: Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. <i>Br J Haematol.</i> 2001; <b>115</b>(4): 983–90. <a target=xrefwindow id=d252e5168 href="http://www.ncbi.nlm.nih.gov/pubmed/11843837">PubMed Abstract </a> | <a target=xrefwindow id=d252e5171 href="http://dx.doi.org/10.1046/j.1365-2141.2001.03148.x">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d252e5180 class=n-a></a>Liu C, Kawedia JD, Cheng C, <i> et al.</i>: Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. <i>Leukemia.</i> 2012; <b>26</b>(11): 2303–9. <a target=xrefwindow id=d252e5191 href="http://www.ncbi.nlm.nih.gov/pubmed/22484422">PubMed Abstract </a> | <a target=xrefwindow id=d252e5194 href="http://dx.doi.org/10.1038/leu.2012.102">Publisher Full Text </a> | <a target=xrefwindow id=d252e5198 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3516853">Free Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725503449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5207 class=n-a></a>Fernandez CA, Smith C, Yang W, <i> et al.</i>: Genome-wide analysis links <i>NFATC2</i> with asparaginase hypersensitivity. <i>Blood.</i> 2015; <b>126</b>(1): 69–75. <a target=xrefwindow id=d252e5221 href="http://www.ncbi.nlm.nih.gov/pubmed/25987655">PubMed Abstract </a> | <a target=xrefwindow id=d252e5225 href="http://dx.doi.org/10.1182/blood-2015-02-628800">Publisher Full Text </a> | <a target=xrefwindow id=d252e5228 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4492197">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725503449">F1000 Recommendation</a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726183737"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5242 class=n-a></a>van der Sluis IM, Vrooman LM, Pieters R, <i> et al.</i>: Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. <i>Haematologica.</i> 2016; <b>101</b>(3): 279–85. <a target=xrefwindow id=d252e5253 href="http://www.ncbi.nlm.nih.gov/pubmed/26928249">PubMed Abstract </a> | <a target=xrefwindow id=d252e5256 href="http://dx.doi.org/10.3324/haematol.2015.137380">Publisher Full Text </a> | <a target=xrefwindow id=d252e5260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4815719">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726183737">F1000 Recommendation</a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d252e5273 class=n-a></a>Wang B, Relling MV, Storm MC, <i> et al.</i>: Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. <i>Leukemia.</i> 2003; <b>17</b>(8): 1583–8. <a target=xrefwindow id=d252e5284 href="http://www.ncbi.nlm.nih.gov/pubmed/12886246">PubMed Abstract </a> | <a target=xrefwindow id=d252e5287 href="http://dx.doi.org/10.1038/sj.leu.2403011">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d252e5296 class=n-a></a>Tong WH, Pieters R, de Groot-Kruseman HA, <i> et al.</i>: The toxicity of very prolonged courses of PEGasparaginase or <i>Erwinia</i> asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. <i>Haematologica.</i> 2014; <b>99</b>(11): 1716–21. <a target=xrefwindow id=d252e5310 href="http://www.ncbi.nlm.nih.gov/pubmed/25150254">PubMed Abstract </a> | <a target=xrefwindow id=d252e5314 href="http://dx.doi.org/10.3324/haematol.2014.109413">Publisher Full Text </a> | <a target=xrefwindow id=d252e5317 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4222477">Free Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d252e5326 class=n-a></a>Silverman LB, Supko JG, Stevenson KE, <i> et al.</i>: Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. <i>Blood.</i> 2010; <b>115</b>(7): 1351–3. <a target=xrefwindow id=d252e5337 href="http://www.ncbi.nlm.nih.gov/pubmed/20007809">PubMed Abstract </a> | <a target=xrefwindow id=d252e5340 href="http://dx.doi.org/10.1182/blood-2009-09-245951">Publisher Full Text </a> | <a target=xrefwindow id=d252e5344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2826760">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d252e5353 class=n-a></a>Henriksen LT, Harila-Saari A, Ruud E, <i> et al.</i>: PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(3): 427–33. <a target=xrefwindow id=d252e5364 href="http://www.ncbi.nlm.nih.gov/pubmed/25418987">PubMed Abstract </a> | <a target=xrefwindow id=d252e5367 href="http://dx.doi.org/10.1002/pbc.25319">Publisher Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d252e5376 class=n-a></a>Vrooman LM, Kirov II, Dreyer ZE, <i> et al.</i>: Activity and Toxicity of Intravenous <i>Erwinia</i> Asparaginase Following Allergy to <i>E. coli</i>-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(2): 228–33. <a target=xrefwindow id=d252e5394 href="http://www.ncbi.nlm.nih.gov/pubmed/26376459">PubMed Abstract </a> | <a target=xrefwindow id=d252e5397 href="http://dx.doi.org/10.1002/pbc.25757">Publisher Full Text </a> | <a target=xrefwindow id=d252e5400 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4715717">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d252e5410 class=n-a></a>Liu C, Yang W, Devidas M, <i> et al.</i>: Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>J Clin Oncol.</i> 2016; <b>34</b>(18): 2133–40. <a target=xrefwindow id=d252e5421 href="http://www.ncbi.nlm.nih.gov/pubmed/27114598">PubMed Abstract </a> | <a target=xrefwindow id=d252e5424 href="http://dx.doi.org/10.1200/JCO.2015.64.5812">Publisher Full Text </a> | <a target=xrefwindow id=d252e5428 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4962704">Free Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d252e5437 class=n-a></a>Ko RH, Jones TL, Radvinsky D, <i> et al.</i>: Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. <i>Cancer.</i> 2015; <b>121</b>(23): 4205–11. <a target=xrefwindow id=d252e5448 href="http://www.ncbi.nlm.nih.gov/pubmed/26308766">PubMed Abstract </a> | <a target=xrefwindow id=d252e5451 href="http://dx.doi.org/10.1002/cncr.29641">Publisher Full Text </a> | <a target=xrefwindow id=d252e5455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4795901">Free Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d252e5464 class=n-a></a>Offman MN, Krol M, Patel N, <i> et al.</i>: Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. <i>Blood.</i> 2011; <b>117</b>(5): 1614–21. <a target=xrefwindow id=d252e5475 href="http://www.ncbi.nlm.nih.gov/pubmed/21106986">PubMed Abstract </a> | <a target=xrefwindow id=d252e5478 href="http://dx.doi.org/10.1182/blood-2010-07-298422">Publisher Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d252e5487 class=n-a></a>Domenech C, Thomas X, Chabaud S, <i> et al.</i>: l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. <i>Br J Haematol.</i> 2011; <b>153</b>(1): 58–65. <a target=xrefwindow id=d252e5498 href="http://www.ncbi.nlm.nih.gov/pubmed/21332712">PubMed Abstract </a> | <a target=xrefwindow id=d252e5501 href="http://dx.doi.org/10.1111/j.1365-2141.2011.08588.x">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455061"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5510 class=n-a></a>Kumar S, Prabhu AA, Dasu VV, <i> et al.</i>: Batch and fed-batch bioreactor studies for the enhanced production of glutaminase-free L-asparaginase from <i>Pectobacterium carotovorum</i> MTCC 1428. <i>Prep Biochem Biotechnol.</i> 2017; <b>47</b>(1): 74–80. <a target=xrefwindow id=d252e5524 href="http://www.ncbi.nlm.nih.gov/pubmed/27070115">PubMed Abstract </a> | <a target=xrefwindow id=d252e5528 href="http://dx.doi.org/10.1080/10826068.2016.1168841">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455061">F1000 Recommendation</a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d252e5541 class=n-a></a>Chen SH, Pei D, Yang W, <i> et al.</i>: Genetic variations in <i>GRIA1</i> on chromosome 5q33 related to asparaginase hypersensitivity. <i>Clin Pharmacol Ther.</i> 2010; <b>88</b>(2): 191–6. <a target=xrefwindow id=d252e5555 href="http://www.ncbi.nlm.nih.gov/pubmed/20592726">PubMed Abstract </a> | <a target=xrefwindow id=d252e5559 href="http://dx.doi.org/10.1038/clpt.2010.94">Publisher Full Text </a> | <a target=xrefwindow id=d252e5562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3000799">Free Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d252e5572 class=n-a></a>Fernandez CA, Smith C, Yang W, <i> et al.</i>: <i>HLA-DRB1</i>*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood.</i> 2014; <b>124</b>(8): 1266–76. <a target=xrefwindow id=d252e5586 href="http://www.ncbi.nlm.nih.gov/pubmed/24970932">PubMed Abstract </a> | <a target=xrefwindow id=d252e5590 href="http://dx.doi.org/10.1182/blood-2014-03-563742">Publisher Full Text </a> | <a target=xrefwindow id=d252e5593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4141516">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d252e5602 class=n-a></a>Knoderer HM, Robarge J, Flockhart DA: Predicting asparaginase-associated pancreatitis. <i>Pediatr Blood Cancer.</i> 2007; <b>49</b>(5): 634–9. <a target=xrefwindow id=d252e5610 href="http://www.ncbi.nlm.nih.gov/pubmed/16937362">PubMed Abstract </a> | <a target=xrefwindow id=d252e5613 href="http://dx.doi.org/10.1002/pbc.21037">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d252e5622 class=n-a></a>Kearney SL, Dahlberg SE, Levy DE, <i> et al.</i>: Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. <i>Pediatr Blood Cancer.</i> 2009; <b>53</b>(2): 162–7. <a target=xrefwindow id=d252e5633 href="http://www.ncbi.nlm.nih.gov/pubmed/19405141">PubMed Abstract </a> | <a target=xrefwindow id=d252e5636 href="http://dx.doi.org/10.1002/pbc.22076">Publisher Full Text </a> | <a target=xrefwindow id=d252e5640 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2721691">Free Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d252e5649 class=n-a></a>Samarasinghe S, Dhir S, Slack J, <i> et al.</i>: Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. <i>Br J Haematol.</i> 2013; <b>162</b>(5): 710–3. <a target=xrefwindow id=d252e5660 href="http://www.ncbi.nlm.nih.gov/pubmed/23750892">PubMed Abstract </a> | <a target=xrefwindow id=d252e5663 href="http://dx.doi.org/10.1111/bjh.12407">Publisher Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d252e5672 class=n-a></a>Raja RA, Schmiegelow K, Albertsen BK, <i> et al.</i>: Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. <i>Br J Haematol.</i> 2014; <b>165</b>(1): 126–33. <a target=xrefwindow id=d252e5683 href="http://www.ncbi.nlm.nih.gov/pubmed/24428625">PubMed Abstract </a> | <a target=xrefwindow id=d252e5686 href="http://dx.doi.org/10.1111/bjh.12733">Publisher Full Text </a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725924636"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5695 class=n-a></a>Place AE, Stevenson KE, Vrooman LM, <i> et al.</i>: Intravenous pegylated asparaginase versus intramuscular native <i>Escherichia coli</i> L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(16): 1677–90. <a target=xrefwindow id=d252e5709 href="http://www.ncbi.nlm.nih.gov/pubmed/26549586">PubMed Abstract </a> | <a target=xrefwindow id=d252e5713 href="http://dx.doi.org/10.1016/S1470-2045(15)00363-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725924636">F1000 Recommendation</a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d252e5727 class=n-a></a>Wolthers BO, Frandsen TL, Abrahamsson J, <i> et al.</i>: Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. <i>Leukemia.</i> 2017; <b>31</b>(2): 325–32. <a target=xrefwindow id=d252e5738 href="http://www.ncbi.nlm.nih.gov/pubmed/27451978">PubMed Abstract </a> | <a target=xrefwindow id=d252e5741 href="http://dx.doi.org/10.1038/leu.2016.203">Publisher Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d252e5750 class=n-a></a>Wolthers BO, Frandsen TL, Baruchel A, <i> et al.</i>: Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. <i>Blood.</i> 2016; <b>128</b>: 585. <a target=xrefwindow id=d252e5761 href="http://www.bloodjournal.org/content/128/22/585?sso-checked=true">Reference Source</a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a name=d252e5770 class=n-a></a>Morinville VD, Husain SZ, Bai H, <i> et al.</i>: Definitions of pediatric pancreatitis and survey of present clinical practices. <i>J Pediatr Gastroenterol Nutr.</i> 2012; <b>55</b>(3): 261–5. <a target=xrefwindow id=d252e5781 href="http://www.ncbi.nlm.nih.gov/pubmed/22357117">PubMed Abstract </a> | <a target=xrefwindow id=d252e5784 href="http://dx.doi.org/10.1097/MPG.0b013e31824f1516">Publisher Full Text </a> | <a target=xrefwindow id=d252e5788 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3626452">Free Full Text </a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d252e5797 class=n-a></a>Forsmark CE, Vege SS, Wilcox CM: Acute Pancreatitis. <i>N Engl J Med.</i> 2016; <b>375</b>(20): 1972–81. <a target=xrefwindow id=d252e5805 href="http://www.ncbi.nlm.nih.gov/pubmed/27959604">PubMed Abstract </a> | <a target=xrefwindow id=d252e5808 href="http://dx.doi.org/10.1056/NEJMra1505202">Publisher Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d252e5817 class=n-a></a>Spraker HL, Spyridis GP, Pui CH, <i> et al.</i>: Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia. <i>J Pediatr Hematol Oncol.</i> 2009; <b>31</b>(12): 957–9. <a target=xrefwindow id=d252e5828 href="http://www.ncbi.nlm.nih.gov/pubmed/19956023">PubMed Abstract </a> | <a target=xrefwindow id=d252e5831 href="http://dx.doi.org/10.1097/MPH.0b013e3181ba9e6a">Publisher Full Text </a> | <a target=xrefwindow id=d252e5835 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2811578">Free Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d252e5844 class=n-a></a>Wu SF, Chen AC, Peng CT, <i> et al.</i>: Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2008; <b>51</b>(6): 824–5. <a target=xrefwindow id=d252e5855 href="http://www.ncbi.nlm.nih.gov/pubmed/18726919">PubMed Abstract </a> | <a target=xrefwindow id=d252e5858 href="http://dx.doi.org/10.1002/pbc.21721">Publisher Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d252e5868 class=n-a></a>Tokimasa S, Yamato K: Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia? <i>Br J Haematol.</i> 2012; <b>157</b>(3): 381–2. <a target=xrefwindow id=d252e5876 href="http://www.ncbi.nlm.nih.gov/pubmed/22145577">PubMed Abstract </a> | <a target=xrefwindow id=d252e5879 href="http://dx.doi.org/10.1111/j.1365-2141.2011.08971.x">Publisher Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718438720"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5888 class=n-a></a>Ben Tanfous M, Sharif-Askari B, Ceppi F, <i> et al.</i>: Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. <i>Clin Cancer Res.</i> 2015; <b>21</b>(2): 329–34. <a target=xrefwindow id=d252e5899 href="http://www.ncbi.nlm.nih.gov/pubmed/24907114">PubMed Abstract </a> | <a target=xrefwindow id=d252e5902 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-0508">Publisher Full Text </a> | <a target=xrefwindow id=d252e5906 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4258187">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718438720">F1000 Recommendation</a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726307209"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e5919 class=n-a></a>Kumar S, Ooi CY, Werlin S, <i> et al.</i>: Risk Factors Associated With Pediatric Acute Recurrent and Chronic Pancreatitis: Lessons From INSPPIRE. <i>JAMA Pediatr.</i> 2016; <b>170</b>(6): 562–9. <a target=xrefwindow id=d252e5930 href="http://www.ncbi.nlm.nih.gov/pubmed/27064572">PubMed Abstract </a> | <a target=xrefwindow id=d252e5933 href="http://dx.doi.org/10.1001/jamapediatrics.2015.4955">Publisher Full Text </a> | <a target=xrefwindow id=d252e5937 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5317277">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726307209">F1000 Recommendation</a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d252e5950 class=n-a></a>Blackett PR, Koren E, Blackstock R, <i> et al.</i>: Hyperlipidemia in acute lymphoblastic leukemia. <i>Ann Clin Lab Sci.</i> 1984; <b>14</b>(2): 123–9. <a target=xrefwindow id=d252e5961 href="http://www.ncbi.nlm.nih.gov/pubmed/6585175">PubMed Abstract </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a name=d252e5970 class=n-a></a>Hoogerbrugge N, Jansen H, Hoogerbrugge PM: Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. <i>Leukemia.</i> 1997; <b>11</b>(8): 1377–9. <a target=xrefwindow id=d252e5978 href="http://www.ncbi.nlm.nih.gov/pubmed/9264396">PubMed Abstract </a> | <a target=xrefwindow id=d252e5981 href="http://dx.doi.org/10.1038/sj.leu.2400703">Publisher Full Text </a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d252e5990 class=n-a></a>Cremer P, Lakomek M, Beck W, <i> et al.</i>: The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. <i>Eur J Pediatr.</i> 1988; <b>147</b>(1): 64–7. <a target=xrefwindow id=d252e6001 href="http://www.ncbi.nlm.nih.gov/pubmed/3422190">PubMed Abstract </a> | <a target=xrefwindow id=d252e6004 href="http://dx.doi.org/10.1007/BF00442614">Publisher Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a name=d252e6014 class=n-a></a>Dietel V, Buhrdel P, Hirsch W, <i> et al.</i>: Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia. <i>Klin Padiatr.</i> 2007; <b>219</b>(2): 95–6. <a target=xrefwindow id=d252e6025 href="http://www.ncbi.nlm.nih.gov/pubmed/17405075">PubMed Abstract </a> | <a target=xrefwindow id=d252e6028 href="http://dx.doi.org/10.1055/s-2007-921455">Publisher Full Text </a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a name=d252e6037 class=n-a></a>Kfoury-Baz EM, Nassar RA, Tanios RF, <i> et al.</i>: Plasmapheresis in asparaginase-induced hypertriglyceridemia. <i>Transfusion.</i> 2008; <b>48</b>(6): 1227–30. <a target=xrefwindow id=d252e6048 href="http://www.ncbi.nlm.nih.gov/pubmed/18410253">PubMed Abstract </a> | <a target=xrefwindow id=d252e6051 href="http://dx.doi.org/10.1111/j.1537-2995.2008.01663.x">Publisher Full Text </a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a name=d252e6060 class=n-a></a>Cohen H, Bielorai B, Harats D, <i> et al.</i>: Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2010; <b>54</b>(5): 703–6. <a target=xrefwindow id=d252e6071 href="http://www.ncbi.nlm.nih.gov/pubmed/20063421">PubMed Abstract </a> | <a target=xrefwindow id=d252e6074 href="http://dx.doi.org/10.1002/pbc.22305">Publisher Full Text </a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d252e6083 class=n-a></a>Solano-Páez P, Villegas JA, Colomer I, <i> et al.</i>: L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia. <i>J Pediatr Hematol Oncol.</i> 2011; <b>33</b>(3): e122–4. <a target=xrefwindow id=d252e6094 href="http://www.ncbi.nlm.nih.gov/pubmed/21399528">PubMed Abstract </a> | <a target=xrefwindow id=d252e6097 href="http://dx.doi.org/10.1097/MPH.0b013e3181faf7a1">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d252e6106 class=n-a></a>Yadav D, Pitchumoni CS: Issues in hyperlipidemic pancreatitis. <i>J Clin Gastroenterol.</i> 2003; <b>36</b>(1): 54–62. <a target=xrefwindow id=d252e6114 href="http://www.ncbi.nlm.nih.gov/pubmed/12488710">PubMed Abstract </a> | <a target=xrefwindow id=d252e6117 href="http://dx.doi.org/10.1097/00004836-200301000-00016">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a name=d252e6126 class=n-a></a>Raja RA, Schmiegelow K, Sørensen DN, <i> et al.</i>: Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer.</i> 2017; <b>64</b>(1): 32–8. <a target=xrefwindow id=d252e6137 href="http://www.ncbi.nlm.nih.gov/pubmed/27555294">PubMed Abstract </a> | <a target=xrefwindow id=d252e6140 href="http://dx.doi.org/10.1002/pbc.26183">Publisher Full Text </a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a name=d252e6150 class=n-a></a>Powell C, Chang C, Gershwin ME: Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. <i>Clin Rev Allergy Immunol.</i> 2011; <b>41</b>(1): 102–13. <a target=xrefwindow id=d252e6158 href="http://www.ncbi.nlm.nih.gov/pubmed/21161435">PubMed Abstract </a> | <a target=xrefwindow id=d252e6161 href="http://dx.doi.org/10.1007/s12016-010-8217-z">Publisher Full Text </a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a name=d252e6170 class=n-a></a>Relling MV, Ramsey LB: Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. <i>Hematology Am Soc Hematol Educ Program.</i> 2013; <b>2013</b>: 126–30. <a target=xrefwindow id=d252e6178 href="http://www.ncbi.nlm.nih.gov/pubmed/24319173">PubMed Abstract </a> | <a target=xrefwindow id=d252e6181 href="http://dx.doi.org/10.1182/asheducation-2013.1.126">Publisher Full Text </a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d252e6190 class=n-a></a>Hyde RK, Liu PP: Germline <i>PAX5</i> mutations and B cell leukemia. <i>Nat Genet.</i> 2013; <b>45</b>(10): 1104–5. <a target=xrefwindow id=d252e6201 href="http://www.ncbi.nlm.nih.gov/pubmed/24071841">PubMed Abstract </a> | <a target=xrefwindow id=d252e6204 href="http://dx.doi.org/10.1038/ng.2778">Publisher Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a name=d252e6213 class=n-a></a>Shah S, Schrader KA, Waanders E, <i> et al.</i>: A recurrent germline <i>PAX5</i> mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. <i>Nat Genet.</i> 2013; <b>45</b>(10): 1226–31. <a target=xrefwindow id=d252e6227 href="http://www.ncbi.nlm.nih.gov/pubmed/24013638">PubMed Abstract </a> | <a target=xrefwindow id=d252e6231 href="http://dx.doi.org/10.1038/ng.2754">Publisher Full Text </a> | <a target=xrefwindow id=d252e6234 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3919799">Free Full Text </a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725901956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6243 class=n-a></a>Moriyama T, Metzger ML, Wu G, <i> et al.</i>: Germline genetic variation in <i>ETV6</i> and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncol.</i> 2015; <b>16</b>(16): 1659–66. <a target=xrefwindow id=d252e6257 href="http://www.ncbi.nlm.nih.gov/pubmed/26522332">PubMed Abstract </a> | <a target=xrefwindow id=d252e6261 href="http://dx.doi.org/10.1016/S1470-2045(15)00369-1">Publisher Full Text </a> | <a target=xrefwindow id=d252e6264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4684709">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725901956">F1000 Recommendation</a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725582215"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6277 class=n-a></a>Topka S, Vijai J, Walsh MF, <i> et al.</i>: Germline <i>ETV6</i> Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genet.</i> 2015; <b>11</b>(6): e1005262. <a target=xrefwindow id=d252e6291 href="http://www.ncbi.nlm.nih.gov/pubmed/26102509">PubMed Abstract </a> | <a target=xrefwindow id=d252e6295 href="http://dx.doi.org/10.1371/journal.pgen.1005262">Publisher Full Text </a> | <a target=xrefwindow id=d252e6298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4477877">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725582215">F1000 Recommendation</a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a name=d252e6312 class=n-a></a>Liew E, Owen C: Familial myelodysplastic syndromes: a review of the literature. <i>Haematologica.</i> 2011; <b>96</b>(10): 1536–42. <a target=xrefwindow id=d252e6320 href="http://www.ncbi.nlm.nih.gov/pubmed/21606161">PubMed Abstract </a> | <a target=xrefwindow id=d252e6323 href="http://dx.doi.org/10.3324/haematol.2011.043422">Publisher Full Text </a> | <a target=xrefwindow id=d252e6326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3186316">Free Full Text </a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d252e6335 class=n-a></a>Churchman M, Qian M, Zhang R, <i> et al.</i>: Germline Genetic Variation in <i>IKZF1</i> and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood.</i> 2016; <b>128</b>(22): LBA–2. <a target=xrefwindow id=d252e6349 href="http://www.bloodjournal.org/content/128/22/LBA-2?sso-checked=true">Reference Source</a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d252e6358 class=n-a></a>Schmiegelow K, Lausten Thomsen U, Baruchel A, <i> et al.</i>: High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia. <i>Leukemia.</i> 2012; <b>26</b>(4): 675–81. <a target=xrefwindow id=d252e6369 href="http://www.ncbi.nlm.nih.gov/pubmed/22005784">PubMed Abstract </a> | <a target=xrefwindow id=d252e6372 href="http://dx.doi.org/10.1038/leu.2011.274">Publisher Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725308675"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6381 class=n-a></a>Zhang MY, Churpek JE, Keel SB, <i> et al.</i>: Germline <i>ETV6</i> mutations in familial thrombocytopenia and hematologic malignancy. <i>Nat Genet.</i> 2015; <b>47</b>(2): 180–5. <a target=xrefwindow id=d252e6395 href="http://www.ncbi.nlm.nih.gov/pubmed/25581430">PubMed Abstract </a> | <a target=xrefwindow id=d252e6399 href="http://dx.doi.org/10.1038/ng.3177">Publisher Full Text </a> | <a target=xrefwindow id=d252e6402 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4540357">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725308675">F1000 Recommendation</a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a name=d252e6415 class=n-a></a>Schmiegelow K: Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes. <i>Eur J Med Genet.</i> 2016; <b>59</b>(12): 654–60. <a target=xrefwindow id=d252e6423 href="http://www.ncbi.nlm.nih.gov/pubmed/26876989">PubMed Abstract </a> | <a target=xrefwindow id=d252e6426 href="http://dx.doi.org/10.1016/j.ejmg.2016.02.006">Publisher Full Text </a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a name=d252e6435 class=n-a></a>Buitenkamp TD, Mathôt RA, de Haas V, <i> et al.</i>: Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. <i>Haematologica.</i> 2010; <b>95</b>(7): 1106–13. <a target=xrefwindow id=d252e6446 href="http://www.ncbi.nlm.nih.gov/pubmed/20418240">PubMed Abstract </a> | <a target=xrefwindow id=d252e6449 href="http://dx.doi.org/10.3324/haematol.2009.019778">Publisher Full Text </a> | <a target=xrefwindow id=d252e6453 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2895034">Free Full Text </a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a name=d252e6463 class=n-a></a>Bohnstedt C, Levinsen M, Rosthøj S, <i> et al.</i>: Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. <i>Leukemia.</i> 2013; <b>27</b>(4): 866–70. <a target=xrefwindow id=d252e6474 href="http://www.ncbi.nlm.nih.gov/pubmed/23138181">PubMed Abstract </a> | <a target=xrefwindow id=d252e6477 href="http://dx.doi.org/10.1038/leu.2012.325">Publisher Full Text </a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718174783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6486 class=n-a></a>Buitenkamp TD, Izraeli S, Zimmermann M, <i> et al.</i>: Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. <i>Blood.</i> 2014; <b>123</b>(1): 70–7. <a target=xrefwindow id=d252e6497 href="http://www.ncbi.nlm.nih.gov/pubmed/24222333">PubMed Abstract </a> | <a target=xrefwindow id=d252e6500 href="http://dx.doi.org/10.1182/blood-2013-06-509463">Publisher Full Text </a> | <a target=xrefwindow id=d252e6504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3879907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718174783">F1000 Recommendation</a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a name=d252e6517 class=n-a></a>Borriello A, Locasciulli A, Bianco AM, <i> et al.</i>: A novel Leu153Ser mutation of the Fanconi anemia <i>FANCD2</i> gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia. <i>Leukemia.</i> 2007; <b>21</b>(1): 72–8. <a target=xrefwindow id=d252e6531 href="http://www.ncbi.nlm.nih.gov/pubmed/17096012">PubMed Abstract </a> | <a target=xrefwindow id=d252e6535 href="http://dx.doi.org/10.1038/sj.leu.2404468">Publisher Full Text </a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a name=d252e6544 class=n-a></a>Wimmer K, Kratz CP, Vasen HF, <i> et al.</i>: Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). <i>J Med Genet.</i> 2014; <b>51</b>(6): 355–65. <a target=xrefwindow id=d252e6555 href="http://www.ncbi.nlm.nih.gov/pubmed/24737826">PubMed Abstract </a> | <a target=xrefwindow id=d252e6558 href="http://dx.doi.org/10.1136/jmedgenet-2014-102284">Publisher Full Text </a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725516613"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6567 class=n-a></a>Bougeard G, Renaux-Petel M, Flaman JM, <i> et al.</i>: Revisiting Li-Fraumeni Syndrome From <i>TP53</i> Mutation Carriers. <i>J Clin Oncol.</i> 2015; <b>33</b>(21): 2345–52. <a target=xrefwindow id=d252e6581 href="http://www.ncbi.nlm.nih.gov/pubmed/26014290">PubMed Abstract </a> | <a target=xrefwindow id=d252e6585 href="http://dx.doi.org/10.1200/JCO.2014.59.5728">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725516613">F1000 Recommendation</a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727455076"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6598 class=n-a></a>Schoenaker MH, Suarez F, Szczepanski T, <i> et al.</i>: Treatment of acute leukemia in children with ataxia telangiectasia (A-T). <i>Eur J Med Genet.</i> 2016; <b>59</b>(12): 641–6. <a target=xrefwindow id=d252e6609 href="http://www.ncbi.nlm.nih.gov/pubmed/27238889">PubMed Abstract </a> | <a target=xrefwindow id=d252e6612 href="http://dx.doi.org/10.1016/j.ejmg.2016.05.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727455076">F1000 Recommendation</a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a name=d252e6626 class=n-a></a>Bienemann K, Burkhardt B, Modlich S, <i> et al.</i>: Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. <i>Br J Haematol.</i> 2011; <b>155</b>(4): 468–76. <a target=xrefwindow id=d252e6637 href="http://www.ncbi.nlm.nih.gov/pubmed/21923652">PubMed Abstract </a> | <a target=xrefwindow id=d252e6640 href="http://dx.doi.org/10.1111/j.1365-2141.2011.08863.x">Publisher Full Text </a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a name=d252e6649 class=n-a></a>Karran P, Attard N: Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. <i>Nat Rev Cancer.</i> 2008; <b>8</b>(1): 24–36. <a target=xrefwindow id=d252e6657 href="http://www.ncbi.nlm.nih.gov/pubmed/18097462">PubMed Abstract </a> | <a target=xrefwindow id=d252e6660 href="http://dx.doi.org/10.1038/nrc2292">Publisher Full Text </a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a name=d252e6669 class=n-a></a>Schmiegelow K, Levinsen MF, Attarbaschi A, <i> et al.</i>: Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. <i>J Clin Oncol.</i> 2013; <b>31</b>(19): 2469–76. <a target=xrefwindow id=d252e6680 href="http://www.ncbi.nlm.nih.gov/pubmed/23690411">PubMed Abstract </a> | <a target=xrefwindow id=d252e6683 href="http://dx.doi.org/10.1200/JCO.2012.47.0500">Publisher Full Text </a> | <a target=xrefwindow id=d252e6687 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3807139">Free Full Text </a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725872993"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d252e6696 class=n-a></a>Oskarsson T, Soderhall S, Arvidson J, <i> et al.</i>: Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. <i>Haematologica.</i> 2016; <b>101</b>(1): 68–76. <a target=xrefwindow id=d252e6707 href="http://www.ncbi.nlm.nih.gov/pubmed/26494838">PubMed Abstract </a> | <a target=xrefwindow id=d252e6710 href="http://dx.doi.org/10.3324/haematol.2015.131680">Publisher Full Text </a> | <a target=xrefwindow id=d252e6714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4697893">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725872993">F1000 Recommendation</a></span></li><li><a name=ref-214 class=n-a></a><span class=label>214. </span>&nbsp;<span class=citation><a name=d252e6727 class=n-a></a>Armstrong GT, Kawashima T, Leisenring W, <i> et al.</i>: Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. <i>J Clin Oncol.</i> 2014; <b>32</b>(12): 1218–27. <a target=xrefwindow id=d252e6738 href="http://www.ncbi.nlm.nih.gov/pubmed/24638000">PubMed Abstract </a> | <a target=xrefwindow id=d252e6741 href="http://dx.doi.org/10.1200/JCO.2013.51.1055">Publisher Full Text </a> | <a target=xrefwindow id=d252e6745 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3986385">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Apr 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-444&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-444&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark<br/> <sup>2</sup> Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark<br/> <sup>3</sup> Department of Diabetes and Metabolism, University Hospital Rigshospitalet, Copenhagen, Denmark<br/> <sup>4</sup> Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-444/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Apr 2017, 6:444 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10768.1">https://doi.org/10.12688/f1000research.10768.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Schmiegelow K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11611 data-id=10768 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10768.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-444/v1/pdf?article_uuid=10a9715d-bc39-4a87-8c5c-181ab38a22c9" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10768.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Schmiegelow K, Müller K, Mogensen SS <em>et al.</em> Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):444 (<a href="https://doi.org/10.12688/f1000research.10768.1" target=_blank>https://doi.org/10.12688/f1000research.10768.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10768 id=mobile-track-article-signin-10768 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10768?target=/articles/6-444"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11611 /> <input name=articleId type=hidden value=10768 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Chris Halsey</strong>, University of Glasgow, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Anne Uyttebroeck</strong>, University Hospitals Leuven, Belgium </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jan Stary</strong>, Department of Pediatric Hematology and Oncology, University Hospital Motol, Czech Republic </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Apr 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-444&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-444&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21725-21478></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=21724-21479></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=3116-21477></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-444/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>07 Apr 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Chris Halsey</strong>, University of Glasgow, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Anne Uyttebroeck</strong>, University Hospitals Leuven, Belgium </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jan Stary</strong>, Department of Pediatric Hematology and Oncology, University Hospital Motol, Czech Republic </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-444&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-444/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Non-infectious chemotherapy-associated acute...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-444/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-444/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-444/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Schmiegelow K et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-444/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-444",
            templates : {
                twitter : "Non-infectious chemotherapy-associated acute toxicities during.... Schmiegelow K et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-444/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10768/11611")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11611");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "21477": 0,
                           "21478": 0,
                           "21479": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "becf309c-b2b1-4ccf-b293-56fd17daef05";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-444.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-444.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-444.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-444.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-444.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>